<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>George Church</title>
    <link>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;v=2.17.6&amp;utm_medium=rss&amp;utm_source=Other&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;ff=20220523181312</link>
    <description>George Church: Latest results from PubMed</description>
    <atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;v=2.17.6&amp;utm_medium=rss&amp;utm_source=Other&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;ff=20220523181312" rel="self"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>PubMed RSS feeds (2.17.6)</generator>
    <language>en</language>
    <lastBuildDate>Mon, 23 May 2022 22:13:14 +0000</lastBuildDate>
    <pubDate>Wed, 11 May 2022 06:00:00 -0400</pubDate>
    <ttl>120</ttl>
    <item>
      <title>Recombineering and MAGE</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/35540496/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Recombination-mediated genetic engineering, also known as recombineering, is the genomic incorporation of homologous single-stranded or double-stranded DNA into bacterial genomes. Recombineering and its derivative methods have radically improved genome engineering capabilities, perhaps none more so than multiplex automated genome engineering (MAGE). MAGE is representative of a set of highly multiplexed single-stranded DNA-mediated technologies. First described in Escherichia coli, both MAGE and...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Methods Primers. 2021;1:7. doi: 10.1038/s43586-020-00006-x. Epub 2021 Jan 14.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recombination-mediated genetic engineering, also known as recombineering, is the genomic incorporation of homologous single-stranded or double-stranded DNA into bacterial genomes. Recombineering and its derivative methods have radically improved genome engineering capabilities, perhaps none more so than multiplex automated genome engineering (MAGE). MAGE is representative of a set of highly multiplexed single-stranded DNA-mediated technologies. First described in <i>Escherichia coli</i>, both MAGE and recombineering are being rapidly translated into diverse prokaryotes and even into eukaryotic cells. Together, this modern set of tools offers the promise of radically improving the scope and throughput of experimental biology by providing powerful new methods to ease the genetic manipulation of model and non-model organisms. In this Primer, we describe recombineering and MAGE, their optimal use, their diverse applications and methods for pairing them with other genetic editing tools. We then look forward to the future of genetic engineering.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/35540496/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">35540496</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC9083505/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC9083505</a> | DOI:<a href=https://doi.org/10.1038/s43586-020-00006-x>10.1038/s43586-020-00006-x</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:35540496</guid>
      <pubDate>Wed, 11 May 2022 06:00:00 -0400</pubDate>
      <dc:creator>Timothy M Wannier</dc:creator>
      <dc:creator>Peter N Ciaccia</dc:creator>
      <dc:creator>Andrew D Ellington</dc:creator>
      <dc:creator>Gabriel T Filsinger</dc:creator>
      <dc:creator>Farren J Isaacs</dc:creator>
      <dc:creator>Kamyab Javanmardi</dc:creator>
      <dc:creator>Michaela A Jones</dc:creator>
      <dc:creator>Aditya M Kunjapur</dc:creator>
      <dc:creator>Akos Nyerges</dc:creator>
      <dc:creator>Csaba Pal</dc:creator>
      <dc:creator>Max G Schubert</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2022-05-11</dc:date>
      <dc:source>Nature reviews. Methods primers</dc:source>
      <dc:title>Recombineering and MAGE</dc:title>
      <dc:identifier>pmid:35540496</dc:identifier>
      <dc:identifier>pmc:PMC9083505</dc:identifier>
      <dc:identifier>doi:10.1038/s43586-020-00006-x</dc:identifier>
    </item>
    <item>
      <title>An integrated pipeline for mammalian genetic screening</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/35474898/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>With the recent advancements in genome editing, next-generation sequencing (NGS), and scalable cloning techniques, scientists can now conduct genetic screens at unprecedented levels of scale and precision. With such a multitude of technologies, there is a need for a simple yet comprehensive pipeline to enable systematic mammalian genetic screening. In this study, we develop unique algorithms for target identification and a toxin-less Gateway cloning tool, termed MegaGate, for library cloning...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Cell Rep Methods. 2021 Sep 27;1(6):100082. doi: 10.1016/j.crmeth.2021.100082. eCollection 2021 Oct 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">With the recent advancements in genome editing, next-generation sequencing (NGS), and scalable cloning techniques, scientists can now conduct genetic screens at unprecedented levels of scale and precision. With such a multitude of technologies, there is a need for a simple yet comprehensive pipeline to enable systematic mammalian genetic screening. In this study, we develop unique algorithms for target identification and a toxin-less Gateway cloning tool, termed MegaGate, for library cloning which, when combined with existing genetic perturbation methods and NGS-coupled readouts, enable versatile engineering of relevant mammalian cell lines. Our integrated pipeline for sequencing-based target ascertainment and modular perturbation screening (STAMPScreen) can thus be utilized for a host of cell state engineering applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/35474898/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">35474898</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC9017118/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC9017118</a> | DOI:<a href=https://doi.org/10.1016/j.crmeth.2021.100082>10.1016/j.crmeth.2021.100082</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:35474898</guid>
      <pubDate>Wed, 27 Apr 2022 06:00:00 -0400</pubDate>
      <dc:creator>Christian Kramme</dc:creator>
      <dc:creator>Alexandru M Plesa</dc:creator>
      <dc:creator>Helen H Wang</dc:creator>
      <dc:creator>Bennett Wolf</dc:creator>
      <dc:creator>Merrick Pierson Smela</dc:creator>
      <dc:creator>Xiaoge Guo</dc:creator>
      <dc:creator>Richie E Kohman</dc:creator>
      <dc:creator>Pranam Chatterjee</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2022-04-27</dc:date>
      <dc:source>Cell reports methods</dc:source>
      <dc:title>An integrated pipeline for mammalian genetic screening</dc:title>
      <dc:identifier>pmid:35474898</dc:identifier>
      <dc:identifier>pmc:PMC9017118</dc:identifier>
      <dc:identifier>doi:10.1016/j.crmeth.2021.100082</dc:identifier>
    </item>
    <item>
      <title>Discovery and validation of human genomic safe harbor sites for gene and cell therapies</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/35474867/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Existing approaches to therapeutic gene transfer are marred by the transient nature of gene expression following non-integrative gene delivery and by safety concerns due to the random mechanism of viral-mediated genomic insertions. The disadvantages of these methods encourage future research in identifying human genomic sites that allow for durable and safe expression of genes of interest. We conducted a bioinformatic search followed by the experimental characterization of human genomic sites,...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Cell Rep Methods. 2022 Jan 14;2(1):100154. doi: 10.1016/j.crmeth.2021.100154. eCollection 2022 Jan 24.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Existing approaches to therapeutic gene transfer are marred by the transient nature of gene expression following non-integrative gene delivery and by safety concerns due to the random mechanism of viral-mediated genomic insertions. The disadvantages of these methods encourage future research in identifying human genomic sites that allow for durable and safe expression of genes of interest. We conducted a bioinformatic search followed by the experimental characterization of human genomic sites, identifying two that demonstrated the stable expression of integrated reporter and therapeutic genes without malignant changes to the cellular transcriptome. The cell-type agnostic criteria used in our bioinformatic search suggest widescale applicability of identified sites for engineering of a diverse range of tissues for clinical and research purposes, including modified T cells for cancer therapy and engineered skin to ameliorate inherited diseases and aging. In addition, the stable and robust levels of gene expression from identified sites allow for the industry-scale biomanufacturing of proteins in human cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/35474867/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">35474867</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC9017210/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC9017210</a> | DOI:<a href=https://doi.org/10.1016/j.crmeth.2021.100154>10.1016/j.crmeth.2021.100154</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:35474867</guid>
      <pubDate>Wed, 27 Apr 2022 06:00:00 -0400</pubDate>
      <dc:creator>Erik Aznauryan</dc:creator>
      <dc:creator>Alexander Yermanos</dc:creator>
      <dc:creator>Elvira Kinzina</dc:creator>
      <dc:creator>Anna Devaux</dc:creator>
      <dc:creator>Edo Kapetanovic</dc:creator>
      <dc:creator>Denitsa Milanova</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Sai T Reddy</dc:creator>
      <dc:date>2022-04-27</dc:date>
      <dc:source>Cell reports methods</dc:source>
      <dc:title>Discovery and validation of human genomic safe harbor sites for gene and cell therapies</dc:title>
      <dc:identifier>pmid:35474867</dc:identifier>
      <dc:identifier>pmc:PMC9017210</dc:identifier>
      <dc:identifier>doi:10.1016/j.crmeth.2021.100154</dc:identifier>
    </item>
    <item>
      <title>Orthogonally induced differentiation of stem cells for the programmatic patterning of vascularized organoids and bioprinted tissues</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/35332307/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The generation of organoids and tissues with programmable cellular complexity, architecture and function would benefit from the simultaneous differentiation of human induced pluripotent stem cells (hiPSCs) into divergent cell types. Yet differentiation protocols for the overexpression of specific transcription factors typically produce a single cell type. Here we show that patterned organoids and bioprinted tissues with controlled composition and organization can be generated by simultaneously...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Biomed Eng. 2022 Apr;6(4):449-462. doi: 10.1038/s41551-022-00856-8. Epub 2022 Mar 24.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The generation of organoids and tissues with programmable cellular complexity, architecture and function would benefit from the simultaneous differentiation of human induced pluripotent stem cells (hiPSCs) into divergent cell types. Yet differentiation protocols for the overexpression of specific transcription factors typically produce a single cell type. Here we show that patterned organoids and bioprinted tissues with controlled composition and organization can be generated by simultaneously co-differentiating hiPSCs into distinct cell types via the forced overexpression of transcription factors, independently of culture-media composition. Specifically, we used such orthogonally induced differentiation to generate endothelial cells and neurons from hiPSCs in a one-pot system containing either neural or endothelial stem-cell-specifying media, and to produce vascularized and patterned cortical organoids within days by aggregating inducible-transcription-factor and wild-type hiPSCs into randomly pooled or multicore-shell embryoid bodies. Moreover, by leveraging multimaterial bioprinting of hiPSC inks without extracellular matrix, we generated patterned neural tissues with layered regions composed of neural stem cells, endothelium and neurons. Orthogonally induced differentiation of stem cells may facilitate the fabrication of engineered tissues for biomedical applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/35332307/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">35332307</a> | DOI:<a href=https://doi.org/10.1038/s41551-022-00856-8>10.1038/s41551-022-00856-8</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:35332307</guid>
      <pubDate>Fri, 25 Mar 2022 06:00:00 -0400</pubDate>
      <dc:creator>Mark A Skylar-Scott</dc:creator>
      <dc:creator>Jeremy Y Huang</dc:creator>
      <dc:creator>Aric Lu</dc:creator>
      <dc:creator>Alex H M Ng</dc:creator>
      <dc:creator>Tomoya Duenki</dc:creator>
      <dc:creator>Songlei Liu</dc:creator>
      <dc:creator>Lucy L Nam</dc:creator>
      <dc:creator>Sarita Damaraju</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Jennifer A Lewis</dc:creator>
      <dc:date>2022-03-25</dc:date>
      <dc:source>Nature biomedical engineering</dc:source>
      <dc:title>Orthogonally induced differentiation of stem cells for the programmatic patterning of vascularized organoids and bioprinted tissues</dc:title>
      <dc:identifier>pmid:35332307</dc:identifier>
      <dc:identifier>doi:10.1038/s41551-022-00856-8</dc:identifier>
    </item>
    <item>
      <title>Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/35263584/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Targeted delivery of therapeutic proteins toward specific cells and across cell membranes remains major challenges. Here, we develop protein-based delivery systems utilizing detoxified single-chain bacterial toxins such as diphtheria toxin (DT) and botulinum neurotoxin (BoNT)-like toxin, BoNT/X, as carriers. The system can deliver large protein cargoes including Cas13a, CasRx, Cas9, and Cre recombinase into cells in a receptor-dependent manner, although delivery of ribonucleoproteins containing...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Cell Rep. 2022 Mar 8;38(10):110476. doi: 10.1016/j.celrep.2022.110476.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Targeted delivery of therapeutic proteins toward specific cells and across cell membranes remains major challenges. Here, we develop protein-based delivery systems utilizing detoxified single-chain bacterial toxins such as diphtheria toxin (DT) and botulinum neurotoxin (BoNT)-like toxin, BoNT/X, as carriers. The system can deliver large protein cargoes including Cas13a, CasRx, Cas9, and Cre recombinase into cells in a receptor-dependent manner, although delivery of ribonucleoproteins containing guide RNAs is not successful. Delivery of Cas13a and CasRx, together with guide RNA expression, reduces mRNAs encoding GFP, SARS-CoV-2 fragments, and endogenous proteins PPIB, KRAS, and CXCR4 in multiple cell lines. Delivery of Cre recombinase modifies the reporter loci in cells. Delivery of Cas9, together with guide RNA expression, generates mutations at the targeted genomic sites in cell lines and induced pluripotent stem cell (iPSC)-derived human neurons. These findings establish modular delivery systems based on single-chain bacterial toxins for delivery of membrane-impermeable therapeutics into targeted cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/35263584/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">35263584</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8958846/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8958846</a> | DOI:<a href=https://doi.org/10.1016/j.celrep.2022.110476>10.1016/j.celrep.2022.110476</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:35263584</guid>
      <pubDate>Wed, 09 Mar 2022 06:00:00 -0500</pubDate>
      <dc:creator>Songhai Tian</dc:creator>
      <dc:creator>Yang Liu</dc:creator>
      <dc:creator>Evan Appleton</dc:creator>
      <dc:creator>Huan Wang</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Min Dong</dc:creator>
      <dc:date>2022-03-09</dc:date>
      <dc:source>Cell reports</dc:source>
      <dc:title>Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms</dc:title>
      <dc:identifier>pmid:35263584</dc:identifier>
      <dc:identifier>pmc:PMC8958846</dc:identifier>
      <dc:identifier>doi:10.1016/j.celrep.2022.110476</dc:identifier>
    </item>
    <item>
      <title>Expanding homogeneous culture of human primordial germ cell-like cells maintaining germline features without serum or feeder layers</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/35148847/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>In vitro expansion of human primordial germ cell-like cells (hPGCLCs), a pluripotent stem cell-derived PGC model, has proved challenging due to rapid loss of primordial germ cell (PGC)-like identity and limited cell survival/proliferation. Here, we describe long-term culture hPGCLCs (LTC-hPGCLCs), which actively proliferate in a serum-free, feeder-free condition without apparent limit as highly homogeneous diploid cell populations maintaining transcriptomic and epigenomic characteristics of...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Stem Cell Reports. 2022 Mar 8;17(3):507-521. doi: 10.1016/j.stemcr.2022.01.012. Epub 2022 Feb 10.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In vitro expansion of human primordial germ cell-like cells (hPGCLCs), a pluripotent stem cell-derived PGC model, has proved challenging due to rapid loss of primordial germ cell (PGC)-like identity and limited cell survival/proliferation. Here, we describe long-term culture hPGCLCs (LTC-hPGCLCs), which actively proliferate in a serum-free, feeder-free condition without apparent limit as highly homogeneous diploid cell populations maintaining transcriptomic and epigenomic characteristics of hPGCLCs. Histone proteomics confirmed reduced H3K9me2 and increased H3K27me3 marks in LTC-hPGCLCs compared with induced pluripotent stem cells (iPSCs). LTC-hPGCLCs established from multiple human iPSC clones of both sexes were telomerase positive, senescence-free cells readily passaged with minimal cell death or deviation from the PGC-like identity. LTC-hPGCLCs are capable of differentiating to DAZL-positive M-spermatogonia-like cells in the xenogeneic reconstituted testis (xrTestis) organ culture milieu as well as efficiently producing fully pluripotent embryonic germ cell-like cells in the presence of stem cell factor and fibroblast growth factor 2. Thus, LTC-hPGCLCs provide convenient access to unlimited amounts of high-quality and homogeneous hPGCLCs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/35148847/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">35148847</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC9039862/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC9039862</a> | DOI:<a href=https://doi.org/10.1016/j.stemcr.2022.01.012>10.1016/j.stemcr.2022.01.012</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:35148847</guid>
      <pubDate>Sat, 12 Feb 2022 06:00:00 -0500</pubDate>
      <dc:creator>Mutsumi Kobayashi</dc:creator>
      <dc:creator>Misato Kobayashi</dc:creator>
      <dc:creator>Junko Odajima</dc:creator>
      <dc:creator>Keiko Shioda</dc:creator>
      <dc:creator>Young Sun Hwang</dc:creator>
      <dc:creator>Kotaro Sasaki</dc:creator>
      <dc:creator>Pranam Chatterjee</dc:creator>
      <dc:creator>Christian Kramme</dc:creator>
      <dc:creator>Richie E Kohman</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Amanda R Loehr</dc:creator>
      <dc:creator>Robert S Weiss</dc:creator>
      <dc:creator>Harald Jüppner</dc:creator>
      <dc:creator>Joanna J Gell</dc:creator>
      <dc:creator>Ching C Lau</dc:creator>
      <dc:creator>Toshi Shioda</dc:creator>
      <dc:date>2022-02-12</dc:date>
      <dc:source>Stem cell reports</dc:source>
      <dc:title>Expanding homogeneous culture of human primordial germ cell-like cells maintaining germline features without serum or feeder layers</dc:title>
      <dc:identifier>pmid:35148847</dc:identifier>
      <dc:identifier>pmc:PMC9039862</dc:identifier>
      <dc:identifier>doi:10.1016/j.stemcr.2022.01.012</dc:identifier>
    </item>
    <item>
      <title>Molecular electronics sensors on a scalable semiconductor chip: A platform for single-molecule measurement of binding kinetics and enzyme activity</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/35074874/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>For nearly 50 years, the vision of using single molecules in circuits has been seen as providing the ultimate miniaturization of electronic chips. An advanced example of such a molecular electronics chip is presented here, with the important distinction that the molecular circuit elements play the role of general-purpose single-molecule sensors. The device consists of a semiconductor chip with a scalable array architecture. Each array element contains a synthetic molecular wire assembled to span...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2112812119. doi: 10.1073/pnas.2112812119.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">For nearly 50 years, the vision of using single molecules in circuits has been seen as providing the ultimate miniaturization of electronic chips. An advanced example of such a molecular electronics chip is presented here, with the important distinction that the molecular circuit elements play the role of general-purpose single-molecule sensors. The device consists of a semiconductor chip with a scalable array architecture. Each array element contains a synthetic molecular wire assembled to span nanoelectrodes in a current monitoring circuit. A central conjugation site is used to attach a single probe molecule that defines the target of the sensor. The chip digitizes the resulting picoamp-scale current-versus-time readout from each sensor element of the array at a rate of 1,000 frames per second. This provides detailed electrical signatures of the single-molecule interactions between the probe and targets present in a solution-phase test sample. This platform is used to measure the interaction kinetics of single molecules, without the use of labels, in a massively parallel fashion. To demonstrate broad applicability, examples are shown for probe molecule binding, including DNA oligos, aptamers, antibodies, and antigens, and the activity of enzymes relevant to diagnostics and sequencing, including a CRISPR/Cas enzyme binding a target DNA, and a DNA polymerase enzyme incorporating nucleotides as it copies a DNA template. All of these applications are accomplished with high sensitivity and resolution, on a manufacturable, scalable, all-electronic semiconductor chip device, thereby bringing the power of modern chips to these diverse areas of biosensing.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/35074874/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">35074874</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8812571/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8812571</a> | DOI:<a href=https://doi.org/10.1073/pnas.2112812119>10.1073/pnas.2112812119</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:35074874</guid>
      <pubDate>Tue, 25 Jan 2022 06:00:00 -0500</pubDate>
      <dc:creator>Carl W Fuller</dc:creator>
      <dc:creator>Pius S Padayatti</dc:creator>
      <dc:creator>Hadi Abderrahim</dc:creator>
      <dc:creator>Lisa Adamiak</dc:creator>
      <dc:creator>Nolan Alagar</dc:creator>
      <dc:creator>Nagaraj Ananthapadmanabhan</dc:creator>
      <dc:creator>Jihye Baek</dc:creator>
      <dc:creator>Sarat Chinni</dc:creator>
      <dc:creator>Chulmin Choi</dc:creator>
      <dc:creator>Kevin J Delaney</dc:creator>
      <dc:creator>Rich Dubielzig</dc:creator>
      <dc:creator>Julie Frkanec</dc:creator>
      <dc:creator>Chris Garcia</dc:creator>
      <dc:creator>Calvin Gardner</dc:creator>
      <dc:creator>Daniel Gebhardt</dc:creator>
      <dc:creator>Tim Geiser</dc:creator>
      <dc:creator>Zachariah Gutierrez</dc:creator>
      <dc:creator>Drew A Hall</dc:creator>
      <dc:creator>Andrew P Hodges</dc:creator>
      <dc:creator>Guangyuan Hou</dc:creator>
      <dc:creator>Sonal Jain</dc:creator>
      <dc:creator>Teresa Jones</dc:creator>
      <dc:creator>Raymond Lobaton</dc:creator>
      <dc:creator>Zsolt Majzik</dc:creator>
      <dc:creator>Allen Marte</dc:creator>
      <dc:creator>Prateek Mohan</dc:creator>
      <dc:creator>Paul Mola</dc:creator>
      <dc:creator>Paul Mudondo</dc:creator>
      <dc:creator>James Mullinix</dc:creator>
      <dc:creator>Thuan Nguyen</dc:creator>
      <dc:creator>Frederick Ollinger</dc:creator>
      <dc:creator>Sarah Orr</dc:creator>
      <dc:creator>Yuxuan Ouyang</dc:creator>
      <dc:creator>Paul Pan</dc:creator>
      <dc:creator>Namseok Park</dc:creator>
      <dc:creator>David Porras</dc:creator>
      <dc:creator>Keshav Prabhu</dc:creator>
      <dc:creator>Cassandra Reese</dc:creator>
      <dc:creator>Travers Ruel</dc:creator>
      <dc:creator>Trevor Sauerbrey</dc:creator>
      <dc:creator>Jaymie R Sawyer</dc:creator>
      <dc:creator>Prem Sinha</dc:creator>
      <dc:creator>Jacky Tu</dc:creator>
      <dc:creator>A G Venkatesh</dc:creator>
      <dc:creator>Sushmitha VijayKumar</dc:creator>
      <dc:creator>Le Zheng</dc:creator>
      <dc:creator>Sungho Jin</dc:creator>
      <dc:creator>James M Tour</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Paul W Mola</dc:creator>
      <dc:creator>Barry Merriman</dc:creator>
      <dc:date>2022-01-25</dc:date>
      <dc:source>Proceedings of the National Academy of Sciences of the United States of America</dc:source>
      <dc:title>Molecular electronics sensors on a scalable semiconductor chip: A platform for single-molecule measurement of binding kinetics and enzyme activity</dc:title>
      <dc:identifier>pmid:35074874</dc:identifier>
      <dc:identifier>pmc:PMC8812571</dc:identifier>
      <dc:identifier>doi:10.1073/pnas.2112812119</dc:identifier>
    </item>
    <item>
      <title>Framework for rapid comparison of extracellular vesicle isolation methods</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34783650/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Extracellular vesicles (EVs) are released by all cells into biofluids and hold great promise as reservoirs of disease biomarkers. One of the main challenges in studying EVs is a lack of methods to quantify EVs that are sensitive enough and can differentiate EVs from similarly sized lipoproteins and protein aggregates. We demonstrate the use of ultrasensitive, single-molecule array (Simoa) assays for the quantification of EVs using three widely expressed transmembrane proteins: the tetraspanins...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Elife. 2021 Nov 16;10:e70725. doi: 10.7554/eLife.70725.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Extracellular vesicles (EVs) are released by all cells into biofluids and hold great promise as reservoirs of disease biomarkers. One of the main challenges in studying EVs is a lack of methods to quantify EVs that are sensitive enough and can differentiate EVs from similarly sized lipoproteins and protein aggregates. We demonstrate the use of ultrasensitive, single-molecule array (Simoa) assays for the quantification of EVs using three widely expressed transmembrane proteins: the tetraspanins CD9, CD63, and CD81. Using Simoa to measure these three EV markers, as well as albumin to measure protein contamination, we were able to compare the relative efficiency and purity of several commonly used EV isolation methods in plasma and cerebrospinal fluid (CSF): ultracentrifugation, precipitation, and size exclusion chromatography (SEC). We further used these assays, all on one platform, to improve SEC isolation from plasma and CSF. Our results highlight the utility of quantifying EV proteins using Simoa and provide a rapid framework for comparing and improving EV isolation methods from biofluids.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34783650/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34783650</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8651285/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8651285</a> | DOI:<a href=https://doi.org/10.7554/eLife.70725>10.7554/eLife.70725</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34783650</guid>
      <pubDate>Tue, 16 Nov 2021 06:00:00 -0500</pubDate>
      <dc:creator>Dmitry Ter-Ovanesyan</dc:creator>
      <dc:creator>Maia Norman</dc:creator>
      <dc:creator>Roey Lazarovits</dc:creator>
      <dc:creator>Wendy Trieu</dc:creator>
      <dc:creator>Ju-Hyun Lee</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>David R Walt</dc:creator>
      <dc:date>2021-11-16</dc:date>
      <dc:source>eLife</dc:source>
      <dc:title>Framework for rapid comparison of extracellular vesicle isolation methods</dc:title>
      <dc:identifier>pmid:34783650</dc:identifier>
      <dc:identifier>pmc:PMC8651285</dc:identifier>
      <dc:identifier>doi:10.7554/eLife.70725</dc:identifier>
    </item>
    <item>
      <title>MegaGate: A toxin-less gateway molecular cloning tool</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34746865/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Gateway cloning employs the use of the ccdb toxin and has low colony numbers, making it difficult to apply at scale to clone libraries of cDNA vectors. In this protocol, we describe MegaGate, a toxin-less Gateway technology capable of robust cDNA library cloning that is efficient, cheap, and scalable. MegaGate eliminates the ccdb toxin used in Gateway recombinase cloning and instead utilizes meganuclease-mediated digestion to eliminate background vectors during cloning and is 99.8% efficient...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">STAR Protoc. 2021 Oct 22;2(4):100907. doi: 10.1016/j.xpro.2021.100907. eCollection 2021 Dec 17.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gateway cloning employs the use of the <i>ccdb</i> toxin and has low colony numbers, making it difficult to apply at scale to clone libraries of cDNA vectors. In this protocol, we describe MegaGate, a toxin-less Gateway technology capable of robust cDNA library cloning that is efficient, cheap, and scalable. MegaGate eliminates the <i>ccdb</i> toxin used in Gateway recombinase cloning and instead utilizes meganuclease-mediated digestion to eliminate background vectors during cloning and is 99.8% efficient with high colony numbers. For complete details on the use and execution of this protocol, please refer to Kramme et al. (2021).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34746865/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34746865</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8551244/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8551244</a> | DOI:<a href=https://doi.org/10.1016/j.xpro.2021.100907>10.1016/j.xpro.2021.100907</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34746865</guid>
      <pubDate>Mon, 08 Nov 2021 06:00:00 -0500</pubDate>
      <dc:creator>Christian Kramme</dc:creator>
      <dc:creator>Alexandru M Plesa</dc:creator>
      <dc:creator>Helen H Wang</dc:creator>
      <dc:creator>Bennett Wolf</dc:creator>
      <dc:creator>Merrick Pierson Smela</dc:creator>
      <dc:creator>Xiaoge Guo</dc:creator>
      <dc:creator>Richie E Kohman</dc:creator>
      <dc:creator>Pranam Chatterjee</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-11-08</dc:date>
      <dc:source>STAR protocols</dc:source>
      <dc:title>MegaGate: A toxin-less gateway molecular cloning tool</dc:title>
      <dc:identifier>pmid:34746865</dc:identifier>
      <dc:identifier>pmc:PMC8551244</dc:identifier>
      <dc:identifier>doi:10.1016/j.xpro.2021.100907</dc:identifier>
    </item>
    <item>
      <title>Neuronal Cell-type Engineering by Transcriptional Activation</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34713262/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Gene activation with the CRISPR-Cas system has great implications in studying gene function, controlling cellular behavior, and modulating disease progression. In this review, we survey recent studies on targeted gene activation and multiplexed screening for inducing neuronal differentiation using CRISPR-Cas transcriptional activation (CRISPRa) and open reading frame (ORF) expression. Critical technical parameters of CRISPRa and ORF-based strategies for neuronal programming are presented and...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Front Genome Ed. 2021 Sep 1;3:715697. doi: 10.3389/fgeed.2021.715697. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gene activation with the CRISPR-Cas system has great implications in studying gene function, controlling cellular behavior, and modulating disease progression. In this review, we survey recent studies on targeted gene activation and multiplexed screening for inducing neuronal differentiation using CRISPR-Cas transcriptional activation (CRISPRa) and open reading frame (ORF) expression. Critical technical parameters of CRISPRa and ORF-based strategies for neuronal programming are presented and discussed. In addition, recent progress on <i>in vivo</i> applications of CRISPRa to the nervous system are highlighted. Overall, CRISPRa represents a valuable addition to the experimental toolbox for neuronal cell-type programming.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34713262/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34713262</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8525383/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8525383</a> | DOI:<a href=https://doi.org/10.3389/fgeed.2021.715697>10.3389/fgeed.2021.715697</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34713262</guid>
      <pubDate>Fri, 29 Oct 2021 06:00:00 -0400</pubDate>
      <dc:creator>Songlei Liu</dc:creator>
      <dc:creator>Johannes Striebel</dc:creator>
      <dc:creator>Giovanni Pasquini</dc:creator>
      <dc:creator>Alex H M Ng</dc:creator>
      <dc:creator>Parastoo Khoshakhlagh</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Volker Busskamp</dc:creator>
      <dc:date>2021-10-29</dc:date>
      <dc:source>Frontiers in genome editing</dc:source>
      <dc:title>Neuronal Cell-type Engineering by Transcriptional Activation</dc:title>
      <dc:identifier>pmid:34713262</dc:identifier>
      <dc:identifier>pmc:PMC8525383</dc:identifier>
      <dc:identifier>doi:10.3389/fgeed.2021.715697</dc:identifier>
    </item>
    <item>
      <title>Laboratory-Generated DNA Can Cause Anomalous Pathogen Diagnostic Test Results</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34523989/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The coronavirus disease 2019 (COVID-19) pandemic has brought about the unprecedented expansion of highly sensitive molecular diagnostics as a primary infection control strategy. At the same time, many laboratories have shifted focus to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) research and diagnostic development, leading to large-scale production of SARS-CoV-2 nucleic acids that can interfere with these tests. We have identified multiple instances, in independent laboratories,...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Microbiol Spectr. 2021 Oct 31;9(2):e0031321. doi: 10.1128/Spectrum.00313-21. Epub 2021 Sep 15.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The coronavirus disease 2019 (COVID-19) pandemic has brought about the unprecedented expansion of highly sensitive molecular diagnostics as a primary infection control strategy. At the same time, many laboratories have shifted focus to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) research and diagnostic development, leading to large-scale production of SARS-CoV-2 nucleic acids that can interfere with these tests. We have identified multiple instances, in independent laboratories, in which nucleic acids generated in research settings are suspected to have caused researchers to test positive for SARS-CoV-2 in surveillance testing. In some cases, the affected individuals did not work directly with these nucleic acids but were exposed <i>via</i> a contaminated surface or object. Though researchers have long been vigilant of DNA contaminants, the transfer of these contaminants to SARS-CoV-2 testing samples can result in anomalous test results. The impact of these incidents stretches into the public sphere, placing additional burdens on public health resources, placing affected researchers and their contacts in isolation and quarantine, removing them from the testing pool for 3 months, and carrying the potential to trigger shutdowns of classrooms and workplaces. We report our observations as a call for increased stewardship over nucleic acids with the potential to impact both the use and development of diagnostics. <b>IMPORTANCE</b> To meet the challenges imposed by the COVID-19 pandemic, research laboratories shifted their focus and clinical diagnostic laboratories developed and utilized new assays. Nucleic acid-based testing became widespread and, for the first time, was used as a prophylactic measure. We report 15 cases of researchers at two institutes testing positive for SARS-CoV-2 on routine surveillance tests, in the absence of any symptoms or transmission. These researchers were likely contaminated with nonhazardous nucleic acids generated in the laboratory in the course of developing new SARS-CoV-2 diagnostics. These contaminating nucleic acids were persistent and widespread throughout the laboratory. We report these findings as a cautionary tale to those working with nucleic acids used in diagnostic testing and as a call for careful stewardship of diagnostically relevant molecules. Our conclusions are especially relevant as at-home COVID-19 testing gains traction in the marketplace and these amplicons may impact on the general public.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34523989/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34523989</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8557887/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8557887</a> | DOI:<a href=https://doi.org/10.1128/Spectrum.00313-21>10.1128/Spectrum.00313-21</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34523989</guid>
      <pubDate>Wed, 15 Sep 2021 06:00:00 -0400</pubDate>
      <dc:creator>Lindsey R Robinson-McCarthy</dc:creator>
      <dc:creator>Alexander J Mijalis</dc:creator>
      <dc:creator>Gabriel T Filsinger</dc:creator>
      <dc:creator>Helena de Puig</dc:creator>
      <dc:creator>Nina M Donghia</dc:creator>
      <dc:creator>Thomas E Schaus</dc:creator>
      <dc:creator>Robert A Rasmussen</dc:creator>
      <dc:creator>Raphael Ferreira</dc:creator>
      <dc:creator>Jeantine E Lunshof</dc:creator>
      <dc:creator>George Chao</dc:creator>
      <dc:creator>Dmitry Ter-Ovanesyan</dc:creator>
      <dc:creator>Oliver Dodd</dc:creator>
      <dc:creator>Erkin Kuru</dc:creator>
      <dc:creator>Adama M Sesay</dc:creator>
      <dc:creator>Joshua Rainbow</dc:creator>
      <dc:creator>Andrew C Pawlowski</dc:creator>
      <dc:creator>Timothy M Wannier</dc:creator>
      <dc:creator>Nicolaas M Angenent-Mari</dc:creator>
      <dc:creator>Devora Najjar</dc:creator>
      <dc:creator>Peng Yin</dc:creator>
      <dc:creator>Donald E Ingber</dc:creator>
      <dc:creator>Jenny M Tam</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-09-15</dc:date>
      <dc:source>Microbiology spectrum</dc:source>
      <dc:title>Laboratory-Generated DNA Can Cause Anomalous Pathogen Diagnostic Test Results</dc:title>
      <dc:identifier>pmid:34523989</dc:identifier>
      <dc:identifier>pmc:PMC8557887</dc:identifier>
      <dc:identifier>doi:10.1128/Spectrum.00313-21</dc:identifier>
    </item>
    <item>
      <title>Designing efficient genetic code expansion in Bacillus subtilis to gain biological insights</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34521822/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Bacillus subtilis is a model gram-positive bacterium, commonly used to explore questions across bacterial cell biology and for industrial uses. To enable greater understanding and control of proteins in B. subtilis, here we report broad and efficient genetic code expansion in B. subtilis by incorporating 20 distinct non-standard amino acids within proteins using 3 different families of genetic code expansion systems and two choices of codons. We use these systems to achieve click-labelling,...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Commun. 2021 Sep 14;12(1):5429. doi: 10.1038/s41467-021-25691-4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Bacillus subtilis is a model gram-positive bacterium, commonly used to explore questions across bacterial cell biology and for industrial uses. To enable greater understanding and control of proteins in B. subtilis, here we report broad and efficient genetic code expansion in B. subtilis by incorporating 20 distinct non-standard amino acids within proteins using 3 different families of genetic code expansion systems and two choices of codons. We use these systems to achieve click-labelling, photo-crosslinking, and translational titration. These tools allow us to demonstrate differences between E. coli and B. subtilis stop codon suppression, validate a predicted protein-protein binding interface, and begin to interrogate properties underlying bacterial cytokinesis by precisely modulating cell division dynamics in vivo. We expect that the establishment of this simple and easily accessible chemical biology system in B. subtilis will help uncover an abundance of biological insights and aid genetic code expansion in other organisms.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34521822/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34521822</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8440579/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8440579</a> | DOI:<a href=https://doi.org/10.1038/s41467-021-25691-4>10.1038/s41467-021-25691-4</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34521822</guid>
      <pubDate>Wed, 15 Sep 2021 06:00:00 -0400</pubDate>
      <dc:creator>Devon A Stork</dc:creator>
      <dc:creator>Georgia R Squyres</dc:creator>
      <dc:creator>Erkin Kuru</dc:creator>
      <dc:creator>Katarzyna A Gromek</dc:creator>
      <dc:creator>Jonathan Rittichier</dc:creator>
      <dc:creator>Aditya Jog</dc:creator>
      <dc:creator>Briana M Burton</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Ethan C Garner</dc:creator>
      <dc:creator>Aditya M Kunjapur</dc:creator>
      <dc:date>2021-09-15</dc:date>
      <dc:source>Nature communications</dc:source>
      <dc:title>Designing efficient genetic code expansion in Bacillus subtilis to gain biological insights</dc:title>
      <dc:identifier>pmid:34521822</dc:identifier>
      <dc:identifier>pmc:PMC8440579</dc:identifier>
      <dc:identifier>doi:10.1038/s41467-021-25691-4</dc:identifier>
    </item>
    <item>
      <title>Cell therapy strategies for COVID-19: Current approaches and potential applications</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34380619/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Coronavirus disease 2019 (COVID-19) continues to burden society worldwide. Despite most patients having a mild course, severe presentations have limited treatment options. COVID-19 manifestations extend beyond the lungs and may affect the cardiovascular, nervous, and other organ systems. Current treatments are nonspecific and do not address potential long-term consequences such as pulmonary fibrosis, demyelination, and ischemic organ damage. Cell therapies offer great potential in treating...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Sci Adv. 2021 Aug 11;7(33):eabg5995. doi: 10.1126/sciadv.abg5995. Print 2021 Aug.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Coronavirus disease 2019 (COVID-19) continues to burden society worldwide. Despite most patients having a mild course, severe presentations have limited treatment options. COVID-19 manifestations extend beyond the lungs and may affect the cardiovascular, nervous, and other organ systems. Current treatments are nonspecific and do not address potential long-term consequences such as pulmonary fibrosis, demyelination, and ischemic organ damage. Cell therapies offer great potential in treating severe COVID-19 presentations due to their customizability and regenerative function. This review summarizes COVID-19 pathogenesis, respective areas where cell therapies have potential, and the ongoing 89 cell therapy trials in COVID-19 as of 1 January 2021.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34380619/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34380619</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8357240/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8357240</a> | DOI:<a href=https://doi.org/10.1126/sciadv.abg5995>10.1126/sciadv.abg5995</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34380619</guid>
      <pubDate>Thu, 12 Aug 2021 06:00:00 -0400</pubDate>
      <dc:creator>Mark M Zaki</dc:creator>
      <dc:creator>Emal Lesha</dc:creator>
      <dc:creator>Khaled Said</dc:creator>
      <dc:creator>Kiavash Kiaee</dc:creator>
      <dc:creator>Lindsey Robinson-McCarthy</dc:creator>
      <dc:creator>Haydy George</dc:creator>
      <dc:creator>Angy Hanna</dc:creator>
      <dc:creator>Evan Appleton</dc:creator>
      <dc:creator>Songlei Liu</dc:creator>
      <dc:creator>Alex H M Ng</dc:creator>
      <dc:creator>Parastoo Khoshakhlagh</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-08-12</dc:date>
      <dc:source>Science advances</dc:source>
      <dc:title>Cell therapy strategies for COVID-19: Current approaches and potential applications</dc:title>
      <dc:identifier>pmid:34380619</dc:identifier>
      <dc:identifier>pmc:PMC8357240</dc:identifier>
      <dc:identifier>doi:10.1126/sciadv.abg5995</dc:identifier>
    </item>
    <item>
      <title>Synthetic auxotrophy remains stable after continuous evolution and in coculture with mammalian cells</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34215581/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Understanding the evolutionary stability and possible context dependence of biological containment techniques is critical as engineered microbes are increasingly under consideration for applications beyond biomanufacturing. While synthetic auxotrophy previously prevented Escherichia coli from exhibiting detectable escape from batch cultures, its long-term effectiveness is unknown. Here, we report automated continuous evolution of a synthetic auxotroph while supplying a decreasing concentration...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Sci Adv. 2021 Jul 2;7(27):eabf5851. doi: 10.1126/sciadv.abf5851. Print 2021 Jul.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Understanding the evolutionary stability and possible context dependence of biological containment techniques is critical as engineered microbes are increasingly under consideration for applications beyond biomanufacturing. While synthetic auxotrophy previously prevented <i>Escherichia coli</i> from exhibiting detectable escape from batch cultures, its long-term effectiveness is unknown. Here, we report automated continuous evolution of a synthetic auxotroph while supplying a decreasing concentration of essential biphenylalanine (BipA). After 100 days of evolution, triplicate populations exhibit no observable escape and exhibit normal growth rates at 10-fold lower BipA concentration than the ancestral synthetic auxotroph. Allelic reconstruction reveals the contribution of three genes to increased fitness at low BipA concentrations. Based on its evolutionary stability, we introduce the progenitor strain directly to mammalian cell culture and observe containment of bacteria without detrimental effects on HEK293T cells. Overall, our findings reveal that synthetic auxotrophy is effective on time scales and in contexts that enable diverse applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34215581/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34215581</a> | DOI:<a href=https://doi.org/10.1126/sciadv.abf5851>10.1126/sciadv.abf5851</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34215581</guid>
      <pubDate>Sat, 03 Jul 2021 06:00:00 -0400</pubDate>
      <dc:creator>Aditya M Kunjapur</dc:creator>
      <dc:creator>Michael G Napolitano</dc:creator>
      <dc:creator>Eriona Hysolli</dc:creator>
      <dc:creator>Karen Noguera</dc:creator>
      <dc:creator>Evan M Appleton</dc:creator>
      <dc:creator>Max G Schubert</dc:creator>
      <dc:creator>Michaela A Jones</dc:creator>
      <dc:creator>Siddharth Iyer</dc:creator>
      <dc:creator>Daniel J Mandell</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-07-03</dc:date>
      <dc:source>Science advances</dc:source>
      <dc:title>Synthetic auxotrophy remains stable after continuous evolution and in coculture with mammalian cells</dc:title>
      <dc:identifier>pmid:34215581</dc:identifier>
      <dc:identifier>doi:10.1126/sciadv.abf5851</dc:identifier>
    </item>
    <item>
      <title>Deep representation learning improves prediction of LacI-mediated transcriptional repression</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34187888/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Recent progress in DNA synthesis and sequencing technology has enabled systematic studies of protein function at a massive scale. We explore a deep mutational scanning study that measured the transcriptional repression function of 43,669 variants of the Escherichia coli LacI protein. We analyze structural and evolutionary aspects that relate to how the function of this protein is maintained, including an in-depth look at the C-terminal domain. We develop a deep neural network to predict...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):e2022838118. doi: 10.1073/pnas.2022838118.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent progress in DNA synthesis and sequencing technology has enabled systematic studies of protein function at a massive scale. We explore a deep mutational scanning study that measured the transcriptional repression function of 43,669 variants of the <i>Escherichia coli</i> LacI protein. We analyze structural and evolutionary aspects that relate to how the function of this protein is maintained, including an in-depth look at the C-terminal domain. We develop a deep neural network to predict transcriptional repression mediated by the lac repressor of <i>Escherichia coli</i> using experimental measurements of variant function. When measured across 10 separate training and validation splits using 5,009 single mutations of the lac repressor, our best-performing model achieved a median Pearson correlation of 0.79, exceeding any previous model. We demonstrate that deep representation learning approaches, first trained in an unsupervised manner across millions of diverse proteins, can be fine-tuned in a supervised fashion using lac repressor experimental datasets to more effectively predict a variant's effect on repression. These findings suggest a deep representation learning model may improve the prediction of other important properties of proteins.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34187888/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34187888</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8271634/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8271634</a> | DOI:<a href=https://doi.org/10.1073/pnas.2022838118>10.1073/pnas.2022838118</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34187888</guid>
      <pubDate>Wed, 30 Jun 2021 06:00:00 -0400</pubDate>
      <dc:creator>Alexander S Garruss</dc:creator>
      <dc:creator>Katherine M Collins</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-06-30</dc:date>
      <dc:source>Proceedings of the National Academy of Sciences of the United States of America</dc:source>
      <dc:title>Deep representation learning improves prediction of LacI-mediated transcriptional repression</dc:title>
      <dc:identifier>pmid:34187888</dc:identifier>
      <dc:identifier>pmc:PMC8271634</dc:identifier>
      <dc:identifier>doi:10.1073/pnas.2022838118</dc:identifier>
    </item>
    <item>
      <title>L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34092791/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>L1CAM is a transmembrane protein expressed on neurons that was presumed to be found on neuron-derived extracellular vesicles (NDEVs) in human biofluids. We developed a panel of single-molecule array assays to evaluate the use of L1CAM for NDEV isolation. We demonstrate that L1CAM is not associated with extracellular vesicles in human plasma or cerebrospinal fluid and therefore recommend against its use as a marker in NDEV isolation protocols.</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Methods. 2021 Jun;18(6):631-634. doi: 10.1038/s41592-021-01174-8. Epub 2021 Jun 3.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">L1CAM is a transmembrane protein expressed on neurons that was presumed to be found on neuron-derived extracellular vesicles (NDEVs) in human biofluids. We developed a panel of single-molecule array assays to evaluate the use of L1CAM for NDEV isolation. We demonstrate that L1CAM is not associated with extracellular vesicles in human plasma or cerebrospinal fluid and therefore recommend against its use as a marker in NDEV isolation protocols.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34092791/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34092791</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC9075416/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC9075416</a> | DOI:<a href=https://doi.org/10.1038/s41592-021-01174-8>10.1038/s41592-021-01174-8</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34092791</guid>
      <pubDate>Mon, 07 Jun 2021 06:00:00 -0400</pubDate>
      <dc:creator>Maia Norman</dc:creator>
      <dc:creator>Dmitry Ter-Ovanesyan</dc:creator>
      <dc:creator>Wendy Trieu</dc:creator>
      <dc:creator>Roey Lazarovits</dc:creator>
      <dc:creator>Emma J K Kowal</dc:creator>
      <dc:creator>Ju Hyun Lee</dc:creator>
      <dc:creator>Alice S Chen-Plotkin</dc:creator>
      <dc:creator>Aviv Regev</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>David R Walt</dc:creator>
      <dc:date>2021-06-07</dc:date>
      <dc:source>Nature methods</dc:source>
      <dc:title>L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma</dc:title>
      <dc:identifier>pmid:34092791</dc:identifier>
      <dc:identifier>pmc:PMC9075416</dc:identifier>
      <dc:identifier>doi:10.1038/s41592-021-01174-8</dc:identifier>
    </item>
    <item>
      <title>Enhancing CRISPR-Cas9 gRNA efficiency prediction by data integration and deep learning</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/34050182/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The design of CRISPR gRNAs requires accurate on-target efficiency predictions, which demand high-quality gRNA activity data and efficient modeling. To advance, we here report on the generation of on-target gRNA activity data for 10,592 SpCas9 gRNAs. Integrating these with complementary published data, we train a deep learning model, CRISPRon, on 23,902 gRNAs. Compared to existing tools, CRISPRon exhibits significantly higher prediction performances on four test datasets not overlapping with...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Commun. 2021 May 28;12(1):3238. doi: 10.1038/s41467-021-23576-0.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The design of CRISPR gRNAs requires accurate on-target efficiency predictions, which demand high-quality gRNA activity data and efficient modeling. To advance, we here report on the generation of on-target gRNA activity data for 10,592 SpCas9 gRNAs. Integrating these with complementary published data, we train a deep learning model, CRISPRon, on 23,902 gRNAs. Compared to existing tools, CRISPRon exhibits significantly higher prediction performances on four test datasets not overlapping with training data used for the development of these tools. Furthermore, we present an interactive gRNA design webserver based on the CRISPRon standalone software, both available via https://rth.dk/resources/crispr/ . CRISPRon advances CRISPR applications by providing more accurate gRNA efficiency predictions than the existing tools.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34050182/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">34050182</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8163799/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8163799</a> | DOI:<a href=https://doi.org/10.1038/s41467-021-23576-0>10.1038/s41467-021-23576-0</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:34050182</guid>
      <pubDate>Sat, 29 May 2021 06:00:00 -0400</pubDate>
      <dc:creator>Xi Xiang</dc:creator>
      <dc:creator>Giulia I Corsi</dc:creator>
      <dc:creator>Christian Anthon</dc:creator>
      <dc:creator>Kunli Qu</dc:creator>
      <dc:creator>Xiaoguang Pan</dc:creator>
      <dc:creator>Xue Liang</dc:creator>
      <dc:creator>Peng Han</dc:creator>
      <dc:creator>Zhanying Dong</dc:creator>
      <dc:creator>Lijun Liu</dc:creator>
      <dc:creator>Jiayan Zhong</dc:creator>
      <dc:creator>Tao Ma</dc:creator>
      <dc:creator>Jinbao Wang</dc:creator>
      <dc:creator>Xiuqing Zhang</dc:creator>
      <dc:creator>Hui Jiang</dc:creator>
      <dc:creator>Fengping Xu</dc:creator>
      <dc:creator>Xin Liu</dc:creator>
      <dc:creator>Xun Xu</dc:creator>
      <dc:creator>Jian Wang</dc:creator>
      <dc:creator>Huanming Yang</dc:creator>
      <dc:creator>Lars Bolund</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Lin Lin</dc:creator>
      <dc:creator>Jan Gorodkin</dc:creator>
      <dc:creator>Yonglun Luo</dc:creator>
      <dc:date>2021-05-29</dc:date>
      <dc:source>Nature communications</dc:source>
      <dc:title>Enhancing CRISPR-Cas9 gRNA efficiency prediction by data integration and deep learning</dc:title>
      <dc:identifier>pmid:34050182</dc:identifier>
      <dc:identifier>pmc:PMC8163799</dc:identifier>
      <dc:identifier>doi:10.1038/s41467-021-23576-0</dc:identifier>
    </item>
    <item>
      <title>High-throughput functional variant screens via in vivo production of single-stranded DNA</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33906944/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Creating and characterizing individual genetic variants remains limited in scale, compared to the tremendous variation both existing in nature and envisioned by genome engineers. Here we introduce retron library recombineering (RLR), a methodology for high-throughput functional screens that surpasses the scale and specificity of CRISPR-Cas methods. We use the targeted reverse-transcription activity of retrons to produce single-stranded DNA (ssDNA) in vivo, incorporating edits at &gt;90% efficiency...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Proc Natl Acad Sci U S A. 2021 May 4;118(18):e2018181118. doi: 10.1073/pnas.2018181118.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Creating and characterizing individual genetic variants remains limited in scale, compared to the tremendous variation both existing in nature and envisioned by genome engineers. Here we introduce retron library recombineering (RLR), a methodology for high-throughput functional screens that surpasses the scale and specificity of CRISPR-Cas methods. We use the targeted reverse-transcription activity of retrons to produce single-stranded DNA (ssDNA) in vivo, incorporating edits at &gt;90% efficiency and enabling multiplexed applications. RLR simultaneously introduces many genomic variants, producing pooled and barcoded variant libraries addressable by targeted deep sequencing. We use RLR for pooled phenotyping of synthesized antibiotic resistance alleles, demonstrating quantitative measurement of relative growth rates. We also perform RLR using the sheared genomic DNA of an evolved bacterium, experimentally querying millions of sequences for causal variants, demonstrating that RLR is uniquely suited to utilize large pools of natural variation. Using ssDNA produced in vivo for pooled experiments presents avenues for exploring variation across the genome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33906944/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33906944</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8106316/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8106316</a> | DOI:<a href=https://doi.org/10.1073/pnas.2018181118>10.1073/pnas.2018181118</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33906944</guid>
      <pubDate>Wed, 28 Apr 2021 06:00:00 -0400</pubDate>
      <dc:creator>Max G Schubert</dc:creator>
      <dc:creator>Daniel B Goodman</dc:creator>
      <dc:creator>Timothy M Wannier</dc:creator>
      <dc:creator>Divjot Kaur</dc:creator>
      <dc:creator>Fahim Farzadfard</dc:creator>
      <dc:creator>Timothy K Lu</dc:creator>
      <dc:creator>Seth L Shipman</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-04-28</dc:date>
      <dc:source>Proceedings of the National Academy of Sciences of the United States of America</dc:source>
      <dc:title>High-throughput functional variant screens via in vivo production of single-stranded DNA</dc:title>
      <dc:identifier>pmid:33906944</dc:identifier>
      <dc:identifier>pmc:PMC8106316</dc:identifier>
      <dc:identifier>doi:10.1073/pnas.2018181118</dc:identifier>
    </item>
    <item>
      <title>Low-N protein engineering with data-efficient deep learning</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33828272/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Protein engineering has enormous academic and industrial potential. However, it is limited by the lack of experimental assays that are consistent with the design goal and sufficiently high throughput to find rare, enhanced variants. Here we introduce a machine learning-guided paradigm that can use as few as 24 functionally assayed mutant sequences to build an accurate virtual fitness landscape and screen ten million sequences via in silico directed evolution. As demonstrated in two dissimilar...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Methods. 2021 Apr;18(4):389-396. doi: 10.1038/s41592-021-01100-y. Epub 2021 Apr 7.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Protein engineering has enormous academic and industrial potential. However, it is limited by the lack of experimental assays that are consistent with the design goal and sufficiently high throughput to find rare, enhanced variants. Here we introduce a machine learning-guided paradigm that can use as few as 24 functionally assayed mutant sequences to build an accurate virtual fitness landscape and screen ten million sequences via in silico directed evolution. As demonstrated in two dissimilar proteins, GFP from Aequorea victoria (avGFP) and E. coli strain TEM-1 β-lactamase, top candidates from a single round are diverse and as active as engineered mutants obtained from previous high-throughput efforts. By distilling information from natural protein sequence landscapes, our model learns a latent representation of 'unnaturalness', which helps to guide search away from nonfunctional sequence neighborhoods. Subsequent low-N supervision then identifies improvements to the activity of interest. In sum, our approach enables efficient use of resource-intensive high-fidelity assays without sacrificing throughput, and helps to accelerate engineered proteins into the fermenter, field and clinic.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33828272/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33828272</a> | DOI:<a href=https://doi.org/10.1038/s41592-021-01100-y>10.1038/s41592-021-01100-y</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33828272</guid>
      <pubDate>Thu, 08 Apr 2021 06:00:00 -0400</pubDate>
      <dc:creator>Surojit Biswas</dc:creator>
      <dc:creator>Grigory Khimulya</dc:creator>
      <dc:creator>Ethan C Alley</dc:creator>
      <dc:creator>Kevin M Esvelt</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-04-08</dc:date>
      <dc:source>Nature methods</dc:source>
      <dc:title>Low-N protein engineering with data-efficient deep learning</dc:title>
      <dc:identifier>pmid:33828272</dc:identifier>
      <dc:identifier>doi:10.1038/s41592-021-01100-y</dc:identifier>
    </item>
    <item>
      <title>Ultrasensitive Measurement of Both SARS-CoV-2 RNA and Antibodies from Saliva</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33755419/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Tests for COVID-19 generally measure SARS-CoV-2 viral RNA from nasal swabs or antibodies against the virus from blood. It has been shown, however, that both viral particles and antibodies against those particles are present in saliva, which is more accessible than both swabs and blood. We present methods for highly sensitive measurements of both viral RNA and antibodies from the same saliva sample. We developed an efficient saliva RNA extraction method and combined it with an ultrasensitive...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Anal Chem. 2021 Apr 6;93(13):5365-5370. doi: 10.1021/acs.analchem.1c00515. Epub 2021 Mar 23.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tests for COVID-19 generally measure SARS-CoV-2 viral RNA from nasal swabs or antibodies against the virus from blood. It has been shown, however, that both viral particles and antibodies against those particles are present in saliva, which is more accessible than both swabs and blood. We present methods for highly sensitive measurements of both viral RNA and antibodies from the same saliva sample. We developed an efficient saliva RNA extraction method and combined it with an ultrasensitive antibody test based on single molecule array (Simoa) technology. We apply our test to the saliva of patients who presented to the hospital with COVID-19 symptoms, some of whom tested positive with a conventional RT-qPCR nasopharyngeal swab test. We demonstrate that combining viral RNA detection by RT-qPCR with antibody detection by Simoa identifies more patients as infected than either method alone. Our results demonstrate the utility of combining viral RNA and antibody testing from saliva, a single easily accessible biofluid.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33755419/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33755419</a> | DOI:<a href=https://doi.org/10.1021/acs.analchem.1c00515>10.1021/acs.analchem.1c00515</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33755419</guid>
      <pubDate>Tue, 23 Mar 2021 06:00:00 -0400</pubDate>
      <dc:creator>Dmitry Ter-Ovanesyan</dc:creator>
      <dc:creator>Tal Gilboa</dc:creator>
      <dc:creator>Roey Lazarovits</dc:creator>
      <dc:creator>Alexandra Rosenthal</dc:creator>
      <dc:creator>Xu Yu</dc:creator>
      <dc:creator>Jonathan Z Li</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>David R Walt</dc:creator>
      <dc:date>2021-03-23</dc:date>
      <dc:source>Analytical chemistry</dc:source>
      <dc:title>Ultrasensitive Measurement of Both SARS-CoV-2 RNA and Antibodies from Saliva</dc:title>
      <dc:identifier>pmid:33755419</dc:identifier>
      <dc:identifier>doi:10.1021/acs.analchem.1c00515</dc:identifier>
    </item>
    <item>
      <title>A computer-guided design tool to increase the efficiency of cellular conversions</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33712564/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Human cell conversion technology has become an important tool for devising new cell transplantation therapies, generating disease models and testing gene therapies. However, while transcription factor over-expression-based methods have shown great promise in generating cell types in vitro, they often endure low conversion efficiency. In this context, great effort has been devoted to increasing the efficiency of current protocols and the development of computational approaches can be of great...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Commun. 2021 Mar 12;12(1):1659. doi: 10.1038/s41467-021-21801-4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human cell conversion technology has become an important tool for devising new cell transplantation therapies, generating disease models and testing gene therapies. However, while transcription factor over-expression-based methods have shown great promise in generating cell types in vitro, they often endure low conversion efficiency. In this context, great effort has been devoted to increasing the efficiency of current protocols and the development of computational approaches can be of great help in this endeavor. Here we introduce a computer-guided design tool that combines a computational framework for prioritizing more efficient combinations of instructive factors (IFs) of cellular conversions, called IRENE, with a transposon-based genomic integration system for efficient delivery. Particularly, IRENE relies on a stochastic gene regulatory network model that systematically prioritizes more efficient IFs by maximizing the agreement of the transcriptional and epigenetic landscapes between the converted and target cells. Our predictions substantially increased the efficiency of two established iPSC-differentiation protocols (natural killer cells and melanocytes) and established the first protocol for iPSC-derived mammary epithelial cells with high efficiency.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33712564/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33712564</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7954801/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7954801</a> | DOI:<a href=https://doi.org/10.1038/s41467-021-21801-4>10.1038/s41467-021-21801-4</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33712564</guid>
      <pubDate>Sat, 13 Mar 2021 06:00:00 -0500</pubDate>
      <dc:creator>Sascha Jung</dc:creator>
      <dc:creator>Evan Appleton</dc:creator>
      <dc:creator>Muhammad Ali</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Antonio Del Sol</dc:creator>
      <dc:date>2021-03-13</dc:date>
      <dc:source>Nature communications</dc:source>
      <dc:title>A computer-guided design tool to increase the efficiency of cellular conversions</dc:title>
      <dc:identifier>pmid:33712564</dc:identifier>
      <dc:identifier>pmc:PMC7954801</dc:identifier>
      <dc:identifier>doi:10.1038/s41467-021-21801-4</dc:identifier>
    </item>
    <item>
      <title>Barcoded oligonucleotides ligated on RNA amplified for multiplexed and parallel in situ analyses</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33693773/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>We present barcoded oligonucleotides ligated on RNA amplified for multiplexed and parallel insitu analyses (BOLORAMIS), a reverse transcription-free method for spatially-resolved, targeted, in situ RNA identification of single or multiple targets. BOLORAMIS was demonstrated on a range of cell types and human cerebral organoids. Singleplex experiments to detect coding and non-coding RNAs in human iPSCs showed a stem-cell signature pattern. Specificity of BOLORAMIS was found to be 92% as...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nucleic Acids Res. 2021 Jun 4;49(10):e58. doi: 10.1093/nar/gkab120.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We present barcoded oligonucleotides ligated on RNA amplified for multiplexed and parallel insitu analyses (BOLORAMIS), a reverse transcription-free method for spatially-resolved, targeted, in situ RNA identification of single or multiple targets. BOLORAMIS was demonstrated on a range of cell types and human cerebral organoids. Singleplex experiments to detect coding and non-coding RNAs in human iPSCs showed a stem-cell signature pattern. Specificity of BOLORAMIS was found to be 92% as illustrated by a clear distinction between human and mouse housekeeping genes in a co-culture system, as well as by recapitulation of subcellular localization of lncRNA MALAT1. Sensitivity of BOLORAMIS was quantified by comparing with single molecule FISH experiments and found to be 11%, 12% and 35% for GAPDH, TFRC and POLR2A, respectively. To demonstrate BOLORAMIS for multiplexed gene analysis, we targeted 96 mRNAs within a co-culture of iNGN neurons and HMC3 human microglial cells. We used fluorescence in situ sequencing to detect error-robust 8-base barcodes associated with each of these genes. We then used this data to uncover the spatial relationship among cells and transcripts by performing single-cell clustering and gene-gene proximity analyses. We anticipate the BOLORAMIS technology for in situ RNA detection to find applications in basic and translational research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33693773/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33693773</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8191787/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8191787</a> | DOI:<a href=https://doi.org/10.1093/nar/gkab120>10.1093/nar/gkab120</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33693773</guid>
      <pubDate>Thu, 11 Mar 2021 06:00:00 -0500</pubDate>
      <dc:creator>Songlei Liu</dc:creator>
      <dc:creator>Sukanya Punthambaker</dc:creator>
      <dc:creator>Eswar P R Iyer</dc:creator>
      <dc:creator>Thomas Ferrante</dc:creator>
      <dc:creator>Daniel Goodwin</dc:creator>
      <dc:creator>Daniel Fürth</dc:creator>
      <dc:creator>Andrew C Pawlowski</dc:creator>
      <dc:creator>Kunal Jindal</dc:creator>
      <dc:creator>Jenny M Tam</dc:creator>
      <dc:creator>Lauren Mifflin</dc:creator>
      <dc:creator>Shahar Alon</dc:creator>
      <dc:creator>Anubhav Sinha</dc:creator>
      <dc:creator>Asmamaw T Wassie</dc:creator>
      <dc:creator>Fei Chen</dc:creator>
      <dc:creator>Anne Cheng</dc:creator>
      <dc:creator>Valerie Willocq</dc:creator>
      <dc:creator>Katharina Meyer</dc:creator>
      <dc:creator>King-Hwa Ling</dc:creator>
      <dc:creator>Conor K Camplisson</dc:creator>
      <dc:creator>Richie E Kohman</dc:creator>
      <dc:creator>John Aach</dc:creator>
      <dc:creator>Je Hyuk Lee</dc:creator>
      <dc:creator>Bruce A Yankner</dc:creator>
      <dc:creator>Edward S Boyden</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-03-11</dc:date>
      <dc:source>Nucleic acids research</dc:source>
      <dc:title>Barcoded oligonucleotides ligated on RNA amplified for multiplexed and parallel in situ analyses</dc:title>
      <dc:identifier>pmid:33693773</dc:identifier>
      <dc:identifier>pmc:PMC8191787</dc:identifier>
      <dc:identifier>doi:10.1093/nar/gkab120</dc:identifier>
    </item>
    <item>
      <title>Lineage barcoding in mice with homing CRISPR</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33692551/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Classic approaches to mapping the developmental history of cells in vivo have relied on techniques that require complex interventions and often capture only a single trajectory or moment in time. We have previously described a developmental barcoding system to address these issues using synthetically induced mutations to record information about each cell's lineage in its genome. This system uses MARC1 mouse lines, which have multiple homing guide RNAs that each generate hundreds of mutant...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Protoc. 2021 Apr;16(4):2088-2108. doi: 10.1038/s41596-020-00485-y. Epub 2021 Mar 10.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Classic approaches to mapping the developmental history of cells in vivo have relied on techniques that require complex interventions and often capture only a single trajectory or moment in time. We have previously described a developmental barcoding system to address these issues using synthetically induced mutations to record information about each cell's lineage in its genome. This system uses MARC1 mouse lines, which have multiple homing guide RNAs that each generate hundreds of mutant alleles and combine to produce an exponential diversity of barcodes. Here, we detail two MARC1 lines that are available from a public repository. We describe strategies for using MARC1 mice and experimental design considerations. We provide a protocol for barcode retrieval and sequencing as well as the analysis of the sequencing data. This protocol generates barcodes based on synthetically induced mutations in mice to enable lineage analysis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33692551/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33692551</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8049957/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8049957</a> | DOI:<a href=https://doi.org/10.1038/s41596-020-00485-y>10.1038/s41596-020-00485-y</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33692551</guid>
      <pubDate>Thu, 11 Mar 2021 06:00:00 -0500</pubDate>
      <dc:creator>Kathleen Leeper</dc:creator>
      <dc:creator>Kian Kalhor</dc:creator>
      <dc:creator>Andyna Vernet</dc:creator>
      <dc:creator>Amanda Graveline</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Prashant Mali</dc:creator>
      <dc:creator>Reza Kalhor</dc:creator>
      <dc:date>2021-03-11</dc:date>
      <dc:source>Nature protocols</dc:source>
      <dc:title>Lineage barcoding in mice with homing CRISPR</dc:title>
      <dc:identifier>pmid:33692551</dc:identifier>
      <dc:identifier>pmc:PMC8049957</dc:identifier>
      <dc:identifier>doi:10.1038/s41596-020-00485-y</dc:identifier>
    </item>
    <item>
      <title>Deep diversification of an AAV capsid protein by machine learning</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33574611/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Modern experimental technologies can assay large numbers of biological sequences, but engineered protein libraries rarely exceed the sequence diversity of natural protein families. Machine learning (ML) models trained directly on experimental data without biophysical modeling provide one route to accessing the full potential diversity of engineered proteins. Here we apply deep learning to design highly diverse adeno-associated virus 2 (AAV2) capsid protein variants that remain viable for...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Biotechnol. 2021 Jun;39(6):691-696. doi: 10.1038/s41587-020-00793-4. Epub 2021 Feb 11.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Modern experimental technologies can assay large numbers of biological sequences, but engineered protein libraries rarely exceed the sequence diversity of natural protein families. Machine learning (ML) models trained directly on experimental data without biophysical modeling provide one route to accessing the full potential diversity of engineered proteins. Here we apply deep learning to design highly diverse adeno-associated virus 2 (AAV2) capsid protein variants that remain viable for packaging of a DNA payload. Focusing on a 28-amino acid segment, we generated 201,426 variants of the AAV2 wild-type (WT) sequence yielding 110,689 viable engineered capsids, 57,348 of which surpass the average diversity of natural AAV serotype sequences, with 12-29 mutations across this region. Even when trained on limited data, deep neural network models accurately predict capsid viability across diverse variants. This approach unlocks vast areas of functional but previously unreachable sequence space, with many potential applications for the generation of improved viral vectors and protein therapeutics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33574611/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33574611</a> | DOI:<a href=https://doi.org/10.1038/s41587-020-00793-4>10.1038/s41587-020-00793-4</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33574611</guid>
      <pubDate>Fri, 12 Feb 2021 06:00:00 -0500</pubDate>
      <dc:creator>Drew H Bryant</dc:creator>
      <dc:creator>Ali Bashir</dc:creator>
      <dc:creator>Sam Sinai</dc:creator>
      <dc:creator>Nina K Jain</dc:creator>
      <dc:creator>Pierce J Ogden</dc:creator>
      <dc:creator>Patrick F Riley</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Lucy J Colwell</dc:creator>
      <dc:creator>Eric D Kelsic</dc:creator>
      <dc:date>2021-02-12</dc:date>
      <dc:source>Nature biotechnology</dc:source>
      <dc:title>Deep diversification of an AAV capsid protein by machine learning</dc:title>
      <dc:identifier>pmid:33574611</dc:identifier>
      <dc:identifier>doi:10.1038/s41587-020-00793-4</dc:identifier>
    </item>
    <item>
      <title>Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33568518/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Nucleic acids are used in many therapeutic modalities, including gene therapy, but their ability to trigger host immune responses in vivo can lead to decreased safety and efficacy. In the case of adeno-associated viral (AAV) vectors, studies have shown that the genome of the vector activates Toll-like receptor 9 (TLR9), a pattern recognition receptor that senses foreign DNA. Here, we engineered AAV vectors to be intrinsically less immunogenic by incorporating short DNA oligonucleotides that...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Sci Transl Med. 2021 Feb 10;13(580):eabd3438. doi: 10.1126/scitranslmed.abd3438.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Nucleic acids are used in many therapeutic modalities, including gene therapy, but their ability to trigger host immune responses in vivo can lead to decreased safety and efficacy. In the case of adeno-associated viral (AAV) vectors, studies have shown that the genome of the vector activates Toll-like receptor 9 (TLR9), a pattern recognition receptor that senses foreign DNA. Here, we engineered AAV vectors to be intrinsically less immunogenic by incorporating short DNA oligonucleotides that antagonize TLR9 activation directly into the vector genome. The engineered vectors elicited markedly reduced innate immune and T cell responses and enhanced gene expression in clinically relevant mouse and pig models across different tissues, including liver, muscle, and retina. Subretinal administration of higher-dose AAV in pigs resulted in photoreceptor pathology with microglia and T cell infiltration. These adverse findings were avoided in the contralateral eyes of the same animals that were injected with the engineered vectors. However, intravitreal injection of higher-dose AAV in macaques, a more immunogenic route of administration, showed that the engineered vector delayed but did not prevent clinical uveitis, suggesting that other immune factors in addition to TLR9 may contribute to intraocular inflammation in this model. Our results demonstrate that linking specific immunomodulatory noncoding sequences to much longer therapeutic nucleic acids can "cloak" the vector from inducing unwanted immune responses in multiple, but not all, models. This "coupled immunomodulation" strategy may widen the therapeutic window for AAV therapies as well as other DNA-based gene transfer methods.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33568518/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33568518</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8409505/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8409505</a> | DOI:<a href=https://doi.org/10.1126/scitranslmed.abd3438>10.1126/scitranslmed.abd3438</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33568518</guid>
      <pubDate>Thu, 11 Feb 2021 06:00:00 -0500</pubDate>
      <dc:creator>Ying Kai Chan</dc:creator>
      <dc:creator>Sean K Wang</dc:creator>
      <dc:creator>Colin J Chu</dc:creator>
      <dc:creator>David A Copland</dc:creator>
      <dc:creator>Alexander J Letizia</dc:creator>
      <dc:creator>Helena Costa Verdera</dc:creator>
      <dc:creator>Jessica J Chiang</dc:creator>
      <dc:creator>Meher Sethi</dc:creator>
      <dc:creator>May K Wang</dc:creator>
      <dc:creator>William J Neidermyer</dc:creator>
      <dc:creator>Yingleong Chan</dc:creator>
      <dc:creator>Elaine T Lim</dc:creator>
      <dc:creator>Amanda R Graveline</dc:creator>
      <dc:creator>Melinda Sanchez</dc:creator>
      <dc:creator>Ryan F Boyd</dc:creator>
      <dc:creator>Thomas S Vihtelic</dc:creator>
      <dc:creator>Rolando Gian Carlo O Inciong</dc:creator>
      <dc:creator>Jared M Slain</dc:creator>
      <dc:creator>Priscilla J Alphonse</dc:creator>
      <dc:creator>Yunlu Xue</dc:creator>
      <dc:creator>Lindsey R Robinson-McCarthy</dc:creator>
      <dc:creator>Jenny M Tam</dc:creator>
      <dc:creator>Maha H Jabbar</dc:creator>
      <dc:creator>Bhubanananda Sahu</dc:creator>
      <dc:creator>Janelle F Adeniran</dc:creator>
      <dc:creator>Manish Muhuri</dc:creator>
      <dc:creator>Phillip W L Tai</dc:creator>
      <dc:creator>Jun Xie</dc:creator>
      <dc:creator>Tyler B Krause</dc:creator>
      <dc:creator>Andyna Vernet</dc:creator>
      <dc:creator>Matthew Pezone</dc:creator>
      <dc:creator>Ru Xiao</dc:creator>
      <dc:creator>Tina Liu</dc:creator>
      <dc:creator>Wei Wang</dc:creator>
      <dc:creator>Henry J Kaplan</dc:creator>
      <dc:creator>Guangping Gao</dc:creator>
      <dc:creator>Andrew D Dick</dc:creator>
      <dc:creator>Federico Mingozzi</dc:creator>
      <dc:creator>Maureen A McCall</dc:creator>
      <dc:creator>Constance L Cepko</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-02-11</dc:date>
      <dc:source>Science translational medicine</dc:source>
      <dc:title>Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses</dc:title>
      <dc:identifier>pmid:33568518</dc:identifier>
      <dc:identifier>pmc:PMC8409505</dc:identifier>
      <dc:identifier>doi:10.1126/scitranslmed.abd3438</dc:identifier>
    </item>
    <item>
      <title>Regulation of host and virus genes by neuronal miR-138 favours herpes simplex virus 1 latency</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33558653/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>MicroRNA miR-138, which is highly expressed in neurons, represses herpes simplex virus 1 (HSV-1) lytic cycle genes by targeting viral ICP0 messenger RNA, thereby promoting viral latency in mice. We found that overexpressed miR-138 also represses lytic processes independently of ICP0 in murine and human neuronal cells; therefore, we investigated whether miR-138 has targets besides ICP0. Using genome-wide RNA sequencing/photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Microbiol. 2021 May;6(5):682-696. doi: 10.1038/s41564-020-00860-1. Epub 2021 Feb 8.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MicroRNA miR-138, which is highly expressed in neurons, represses herpes simplex virus 1 (HSV-1) lytic cycle genes by targeting viral ICP0 messenger RNA, thereby promoting viral latency in mice. We found that overexpressed miR-138 also represses lytic processes independently of ICP0 in murine and human neuronal cells; therefore, we investigated whether miR-138 has targets besides ICP0. Using genome-wide RNA sequencing/photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation followed by short interfering RNA knockdown of candidate targets, we identified the host Oct-1 and Foxc1 messenger mRNAs as miR-138's targets, whose gene products are transcription factors important for HSV-1 replication in neuronal cells. OCT-1 has a known role in the initiation of HSV transcription. Overexpression of FOXC1, which was not known to affect HSV-1, promoted HSV-1 replication in murine neurons and ganglia. CRISPR-Cas9 knockout of FOXC1 reduced viral replication, lytic gene expression and miR-138 repression in murine neuronal cells. FOXC1 also collaborated with ICP0 to decrease heterochromatin on viral genes and compensated for the defect of an ICP0-null virus. In summary, miR-138 targets ICP0, Oct-1 and Foxc1 to repress HSV-1 lytic cycle genes and promote epigenetic gene silencing, which together enable favourable conditions for latent infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33558653/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33558653</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8221016/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8221016</a> | DOI:<a href=https://doi.org/10.1038/s41564-020-00860-1>10.1038/s41564-020-00860-1</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33558653</guid>
      <pubDate>Tue, 09 Feb 2021 06:00:00 -0500</pubDate>
      <dc:creator>Boqiang Sun</dc:creator>
      <dc:creator>Xuewei Yang</dc:creator>
      <dc:creator>Fujun Hou</dc:creator>
      <dc:creator>Xiaofeng Yu</dc:creator>
      <dc:creator>Qiongyan Wang</dc:creator>
      <dc:creator>Hyung Suk Oh</dc:creator>
      <dc:creator>Priya Raja</dc:creator>
      <dc:creator>Jean M Pesola</dc:creator>
      <dc:creator>Emilia A H Vanni</dc:creator>
      <dc:creator>Seamus McCarron</dc:creator>
      <dc:creator>Jenna Morris-Love</dc:creator>
      <dc:creator>Alex H M Ng</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>David M Knipe</dc:creator>
      <dc:creator>Donald M Coen</dc:creator>
      <dc:creator>Dongli Pan</dc:creator>
      <dc:date>2021-02-09</dc:date>
      <dc:source>Nature microbiology</dc:source>
      <dc:title>Regulation of host and virus genes by neuronal miR-138 favours herpes simplex virus 1 latency</dc:title>
      <dc:identifier>pmid:33558653</dc:identifier>
      <dc:identifier>pmc:PMC8221016</dc:identifier>
      <dc:identifier>doi:10.1038/s41564-020-00860-1</dc:identifier>
    </item>
    <item>
      <title>Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33509999/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Methods for highly multiplexed RNA imaging are limited in spatial resolution and thus in their ability to localize transcripts to nanoscale and subcellular compartments. We adapt expansion microscopy, which physically expands biological specimens, for long-read untargeted and targeted in situ RNA sequencing. We applied untargeted expansion sequencing (ExSeq) to the mouse brain, which yielded the readout of thousands of genes, including splice variants. Targeted ExSeq yielded nanoscale-resolution...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Science. 2021 Jan 29;371(6528):eaax2656. doi: 10.1126/science.aax2656.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Methods for highly multiplexed RNA imaging are limited in spatial resolution and thus in their ability to localize transcripts to nanoscale and subcellular compartments. We adapt expansion microscopy, which physically expands biological specimens, for long-read untargeted and targeted in situ RNA sequencing. We applied untargeted expansion sequencing (ExSeq) to the mouse brain, which yielded the readout of thousands of genes, including splice variants. Targeted ExSeq yielded nanoscale-resolution maps of RNAs throughout dendrites and spines in the neurons of the mouse hippocampus, revealing patterns across multiple cell types, layer-specific cell types across the mouse visual cortex, and the organization and position-dependent states of tumor and immune cells in a human metastatic breast cancer biopsy. Thus, ExSeq enables highly multiplexed mapping of RNAs from nanoscale to system scale.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33509999/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33509999</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7900882/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7900882</a> | DOI:<a href=https://doi.org/10.1126/science.aax2656>10.1126/science.aax2656</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33509999</guid>
      <pubDate>Fri, 29 Jan 2021 06:00:00 -0500</pubDate>
      <dc:creator>Shahar Alon</dc:creator>
      <dc:creator>Daniel R Goodwin</dc:creator>
      <dc:creator>Anubhav Sinha</dc:creator>
      <dc:creator>Asmamaw T Wassie</dc:creator>
      <dc:creator>Fei Chen</dc:creator>
      <dc:creator>Evan R Daugharthy</dc:creator>
      <dc:creator>Yosuke Bando</dc:creator>
      <dc:creator>Atsushi Kajita</dc:creator>
      <dc:creator>Andrew G Xue</dc:creator>
      <dc:creator>Karl Marrett</dc:creator>
      <dc:creator>Robert Prior</dc:creator>
      <dc:creator>Yi Cui</dc:creator>
      <dc:creator>Andrew C Payne</dc:creator>
      <dc:creator>Chun-Chen Yao</dc:creator>
      <dc:creator>Ho-Jun Suk</dc:creator>
      <dc:creator>Ru Wang</dc:creator>
      <dc:creator>Chih-Chieh Jay Yu</dc:creator>
      <dc:creator>Paul Tillberg</dc:creator>
      <dc:creator>Paul Reginato</dc:creator>
      <dc:creator>Nikita Pak</dc:creator>
      <dc:creator>Songlei Liu</dc:creator>
      <dc:creator>Sukanya Punthambaker</dc:creator>
      <dc:creator>Eswar P R Iyer</dc:creator>
      <dc:creator>Richie E Kohman</dc:creator>
      <dc:creator>Jeremy A Miller</dc:creator>
      <dc:creator>Ed S Lein</dc:creator>
      <dc:creator>Ana Lako</dc:creator>
      <dc:creator>Nicole Cullen</dc:creator>
      <dc:creator>Scott Rodig</dc:creator>
      <dc:creator>Karla Helvie</dc:creator>
      <dc:creator>Daniel L Abravanel</dc:creator>
      <dc:creator>Nikhil Wagle</dc:creator>
      <dc:creator>Bruce E Johnson</dc:creator>
      <dc:creator>Johanna Klughammer</dc:creator>
      <dc:creator>Michal Slyper</dc:creator>
      <dc:creator>Julia Waldman</dc:creator>
      <dc:creator>Judit Jané-Valbuena</dc:creator>
      <dc:creator>Orit Rozenblatt-Rosen</dc:creator>
      <dc:creator>Aviv Regev</dc:creator>
      <dc:creator>IMAXT Consortium</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Adam H Marblestone</dc:creator>
      <dc:creator>Edward S Boyden</dc:creator>
      <dc:date>2021-01-29</dc:date>
      <dc:source>Science (New York, N.Y.)</dc:source>
      <dc:title>Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems</dc:title>
      <dc:identifier>pmid:33509999</dc:identifier>
      <dc:identifier>pmc:PMC7900882</dc:identifier>
      <dc:identifier>doi:10.1126/science.aax2656</dc:identifier>
    </item>
    <item>
      <title>Delivery of biomacromolecules for therapeutic genome editing</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33482978/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>No abstract</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Adv Drug Deliv Rev. 2021 Jan;168:1-2. doi: 10.1016/j.addr.2020.12.013.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33482978/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33482978</a> | DOI:<a href=https://doi.org/10.1016/j.addr.2020.12.013>10.1016/j.addr.2020.12.013</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33482978</guid>
      <pubDate>Sat, 23 Jan 2021 06:00:00 -0500</pubDate>
      <dc:creator>Yuan Ping</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-01-23</dc:date>
      <dc:source>Advanced drug delivery reviews</dc:source>
      <dc:title>Delivery of biomacromolecules for therapeutic genome editing</dc:title>
      <dc:identifier>pmid:33482978</dc:identifier>
      <dc:identifier>doi:10.1016/j.addr.2020.12.013</dc:identifier>
    </item>
    <item>
      <title>Characterizing the portability of phage-encoded homologous recombination proteins</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33462496/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Efficient genome editing methods are essential for biotechnology and fundamental research. Homologous recombination (HR) is the most versatile method of genome editing, but techniques that rely on host RecA-mediated pathways are inefficient and laborious. Phage-encoded single-stranded DNA annealing proteins (SSAPs) improve HR 1,000-fold above endogenous levels. However, they are not broadly functional. Using Escherichia coli, Lactococcus lactis, Mycobacterium smegmatis, Lactobacillus rhamnosus...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Chem Biol. 2021 Apr;17(4):394-402. doi: 10.1038/s41589-020-00710-5. Epub 2021 Jan 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Efficient genome editing methods are essential for biotechnology and fundamental research. Homologous recombination (HR) is the most versatile method of genome editing, but techniques that rely on host RecA-mediated pathways are inefficient and laborious. Phage-encoded single-stranded DNA annealing proteins (SSAPs) improve HR 1,000-fold above endogenous levels. However, they are not broadly functional. Using Escherichia coli, Lactococcus lactis, Mycobacterium smegmatis, Lactobacillus rhamnosus and Caulobacter crescentus, we investigated the limited portability of SSAPs. We find that these proteins specifically recognize the C-terminal tail of the host's single-stranded DNA-binding protein (SSB) and are portable between species only if compatibility with this host domain is maintained. Furthermore, we find that co-expressing SSAPs with SSBs can significantly improve genome editing efficiency, in some species enabling SSAP functionality even without host compatibility. Finally, we find that high-efficiency HR far surpasses the mutational capacity of commonly used random mutagenesis methods, generating exceptional phenotypes that are inaccessible through sequential nucleotide conversions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33462496/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33462496</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7990699/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7990699</a> | DOI:<a href=https://doi.org/10.1038/s41589-020-00710-5>10.1038/s41589-020-00710-5</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33462496</guid>
      <pubDate>Tue, 19 Jan 2021 06:00:00 -0500</pubDate>
      <dc:creator>Gabriel T Filsinger</dc:creator>
      <dc:creator>Timothy M Wannier</dc:creator>
      <dc:creator>Felix B Pedersen</dc:creator>
      <dc:creator>Isaac D Lutz</dc:creator>
      <dc:creator>Julie Zhang</dc:creator>
      <dc:creator>Devon A Stork</dc:creator>
      <dc:creator>Anik Debnath</dc:creator>
      <dc:creator>Kevin Gozzi</dc:creator>
      <dc:creator>Helene Kuchwara</dc:creator>
      <dc:creator>Verena Volf</dc:creator>
      <dc:creator>Stan Wang</dc:creator>
      <dc:creator>Xavier Rios</dc:creator>
      <dc:creator>Christopher J Gregg</dc:creator>
      <dc:creator>Marc J Lajoie</dc:creator>
      <dc:creator>Seth L Shipman</dc:creator>
      <dc:creator>John Aach</dc:creator>
      <dc:creator>Michael T Laub</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2021-01-19</dc:date>
      <dc:source>Nature chemical biology</dc:source>
      <dc:title>Characterizing the portability of phage-encoded homologous recombination proteins</dc:title>
      <dc:identifier>pmid:33462496</dc:identifier>
      <dc:identifier>pmc:PMC7990699</dc:identifier>
      <dc:identifier>doi:10.1038/s41589-020-00710-5</dc:identifier>
    </item>
    <item>
      <title>Anomalous COVID-19 tests hinder researchers</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33446547/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>No abstract</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Science. 2021 Jan 15;371(6526):244-245. doi: 10.1126/science.abf8873.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33446547/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33446547</a> | DOI:<a href=https://doi.org/10.1126/science.abf8873>10.1126/science.abf8873</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33446547</guid>
      <pubDate>Fri, 15 Jan 2021 06:00:00 -0500</pubDate>
      <dc:creator>Lindsey R Robinson-McCarthy</dc:creator>
      <dc:creator>Alexander J Mijalis</dc:creator>
      <dc:creator>Gabriel T Filsinger</dc:creator>
      <dc:creator>Helena de Puig</dc:creator>
      <dc:creator>Nina M Donghia</dc:creator>
      <dc:creator>Thomas E Schaus</dc:creator>
      <dc:creator>Robert A Rasmussen</dc:creator>
      <dc:creator>Raphael Ferreira</dc:creator>
      <dc:creator>Jeantine E Lunshof</dc:creator>
      <dc:creator>George Chao</dc:creator>
      <dc:creator>Dmitry Ter-Ovanesyan</dc:creator>
      <dc:creator>Oliver Dodd</dc:creator>
      <dc:creator>Erkin Kuru</dc:creator>
      <dc:creator>Adama M Sesay</dc:creator>
      <dc:creator>Joshua Rainbow</dc:creator>
      <dc:creator>Andrew C Pawlowski</dc:creator>
      <dc:creator>Timothy M Wannier</dc:creator>
      <dc:creator>Peng Yin</dc:creator>
      <dc:creator>James J Collins</dc:creator>
      <dc:creator>Donald E Ingber</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Jenny M Tam</dc:creator>
      <dc:date>2021-01-15</dc:date>
      <dc:source>Science (New York, N.Y.)</dc:source>
      <dc:title>Anomalous COVID-19 tests hinder researchers</dc:title>
      <dc:identifier>pmid:33446547</dc:identifier>
      <dc:identifier>doi:10.1126/science.abf8873</dc:identifier>
    </item>
    <item>
      <title>In situ genome sequencing resolves DNA sequence and structure in intact biological samples</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33384301/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Understanding genome organization requires integration of DNA sequence and three-dimensional spatial context; however, existing genome-wide methods lack either base pair sequence resolution or direct spatial localization. Here, we describe in situ genome sequencing (IGS), a method for simultaneously sequencing and imaging genomes within intact biological samples. We applied IGS to human fibroblasts and early mouse embryos, spatially localizing thousands of genomic loci in individual nuclei....</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Science. 2021 Feb 26;371(6532):eaay3446. doi: 10.1126/science.aay3446. Epub 2020 Dec 31.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Understanding genome organization requires integration of DNA sequence and three-dimensional spatial context; however, existing genome-wide methods lack either base pair sequence resolution or direct spatial localization. Here, we describe in situ genome sequencing (IGS), a method for simultaneously sequencing and imaging genomes within intact biological samples. We applied IGS to human fibroblasts and early mouse embryos, spatially localizing thousands of genomic loci in individual nuclei. Using these data, we characterized parent-specific changes in genome structure across embryonic stages, revealed single-cell chromatin domains in zygotes, and uncovered epigenetic memory of global chromosome positioning within individual embryos. These results demonstrate how IGS can directly connect sequence and structure across length scales from single base pairs to whole organisms.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33384301/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33384301</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7962746/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7962746</a> | DOI:<a href=https://doi.org/10.1126/science.aay3446>10.1126/science.aay3446</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33384301</guid>
      <pubDate>Fri, 01 Jan 2021 06:00:00 -0500</pubDate>
      <dc:creator>Andrew C Payne</dc:creator>
      <dc:creator>Zachary D Chiang</dc:creator>
      <dc:creator>Paul L Reginato</dc:creator>
      <dc:creator>Sarah M Mangiameli</dc:creator>
      <dc:creator>Evan M Murray</dc:creator>
      <dc:creator>Chun-Chen Yao</dc:creator>
      <dc:creator>Styliani Markoulaki</dc:creator>
      <dc:creator>Andrew S Earl</dc:creator>
      <dc:creator>Ajay S Labade</dc:creator>
      <dc:creator>Rudolf Jaenisch</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Edward S Boyden</dc:creator>
      <dc:creator>Jason D Buenrostro</dc:creator>
      <dc:creator>Fei Chen</dc:creator>
      <dc:date>2021-01-01</dc:date>
      <dc:source>Science (New York, N.Y.)</dc:source>
      <dc:title>In situ genome sequencing resolves DNA sequence and structure in intact biological samples</dc:title>
      <dc:identifier>pmid:33384301</dc:identifier>
      <dc:identifier>pmc:PMC7962746</dc:identifier>
      <dc:identifier>doi:10.1126/science.aay3446</dc:identifier>
    </item>
    <item>
      <title>Multiplex Single-Molecule Kinetics of Nanopore-Coupled Polymerases</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33370106/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>DNA polymerases have revolutionized the biotechnology field due to their ability to precisely replicate stored genetic information. Screening variants of these enzymes for specific properties gives the opportunity to identify polymerases with different features. We have previously developed a single-molecule DNA sequencing platform by coupling a DNA polymerase to an α-hemolysin pore on a nanopore array. Here, we use this approach to demonstrate a single-molecule method that enables rapid...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">ACS Nano. 2021 Jan 26;15(1):489-502. doi: 10.1021/acsnano.0c05226. Epub 2020 Dec 28.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DNA polymerases have revolutionized the biotechnology field due to their ability to precisely replicate stored genetic information. Screening variants of these enzymes for specific properties gives the opportunity to identify polymerases with different features. We have previously developed a single-molecule DNA sequencing platform by coupling a DNA polymerase to an α-hemolysin pore on a nanopore array. Here, we use this approach to demonstrate a single-molecule method that enables rapid screening of polymerase variants in a multiplex manner. In this approach, barcoded DNA strands are complexed with polymerase variants and serve as templates for nanopore sequencing. Nanopore sequencing of the barcoded DNA reveals both the barcode identity and kinetic properties of the polymerase variant associated with the cognate barcode, allowing for multiplexed investigation of many polymerase variants in parallel on a single nanopore array. Further, we develop a robust classification algorithm that discriminates kinetic characteristics of the different polymerase mutants. As a proof of concept, we demonstrate the utility of our approach by screening a library of ∼100 polymerases to identify variants for potential applications of biotechnological interest. We anticipate our screening method to be broadly useful for applications that require polymerases with altered physical properties.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33370106/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33370106</a> | DOI:<a href=https://doi.org/10.1021/acsnano.0c05226>10.1021/acsnano.0c05226</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33370106</guid>
      <pubDate>Mon, 28 Dec 2020 06:00:00 -0500</pubDate>
      <dc:creator>Mirkó Palla</dc:creator>
      <dc:creator>Sukanya Punthambaker</dc:creator>
      <dc:creator>Benjamin Stranges</dc:creator>
      <dc:creator>Frederic Vigneault</dc:creator>
      <dc:creator>Jeff Nivala</dc:creator>
      <dc:creator>Daniel Wiegand</dc:creator>
      <dc:creator>Aruna Ayer</dc:creator>
      <dc:creator>Timothy Craig</dc:creator>
      <dc:creator>Dmitriy Gremyachinskiy</dc:creator>
      <dc:creator>Helen Franklin</dc:creator>
      <dc:creator>Shaw Sun</dc:creator>
      <dc:creator>James Pollard</dc:creator>
      <dc:creator>Andrew Trans</dc:creator>
      <dc:creator>Cleoma Arnold</dc:creator>
      <dc:creator>Charles Schwab</dc:creator>
      <dc:creator>Colin Mcgaw</dc:creator>
      <dc:creator>Preethi Sarvabhowman</dc:creator>
      <dc:creator>Dhruti Dalal</dc:creator>
      <dc:creator>Eileen Thai</dc:creator>
      <dc:creator>Evan Amato</dc:creator>
      <dc:creator>Ilya Lederman</dc:creator>
      <dc:creator>Meng Taing</dc:creator>
      <dc:creator>Sara Kelley</dc:creator>
      <dc:creator>Adam Qwan</dc:creator>
      <dc:creator>Carl W Fuller</dc:creator>
      <dc:creator>Stefan Roever</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2020-12-28</dc:date>
      <dc:source>ACS nano</dc:source>
      <dc:title>Multiplex Single-Molecule Kinetics of Nanopore-Coupled Polymerases</dc:title>
      <dc:identifier>pmid:33370106</dc:identifier>
      <dc:identifier>doi:10.1021/acsnano.0c05226</dc:identifier>
    </item>
    <item>
      <title>Transparency is key to ethical vaccine research</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33335056/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>No abstract</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Science. 2020 Dec 18;370(6523):1422-1423. doi: 10.1126/science.abf4851.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33335056/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33335056</a> | DOI:<a href=https://doi.org/10.1126/science.abf4851>10.1126/science.abf4851</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33335056</guid>
      <pubDate>Fri, 18 Dec 2020 06:00:00 -0500</pubDate>
      <dc:creator>Preston W Estep</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2020-12-18</dc:date>
      <dc:source>Science (New York, N.Y.)</dc:source>
      <dc:title>Transparency is key to ethical vaccine research</dc:title>
      <dc:identifier>pmid:33335056</dc:identifier>
      <dc:identifier>doi:10.1126/science.abf4851</dc:identifier>
    </item>
    <item>
      <title>Core commitments for field trials of gene drive organisms</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33335055/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>No abstract</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Science. 2020 Dec 18;370(6523):1417-1419. doi: 10.1126/science.abd1908.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33335055/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33335055</a> | DOI:<a href=https://doi.org/10.1126/science.abd1908>10.1126/science.abd1908</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33335055</guid>
      <pubDate>Fri, 18 Dec 2020 06:00:00 -0500</pubDate>
      <dc:creator>Kanya C Long</dc:creator>
      <dc:creator>Luke Alphey</dc:creator>
      <dc:creator>George J Annas</dc:creator>
      <dc:creator>Cinnamon S Bloss</dc:creator>
      <dc:creator>Karl J Campbell</dc:creator>
      <dc:creator>Jackson Champer</dc:creator>
      <dc:creator>Chun-Hong Chen</dc:creator>
      <dc:creator>Amit Choudhary</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>James P Collins</dc:creator>
      <dc:creator>Kimberly L Cooper</dc:creator>
      <dc:creator>Jason A Delborne</dc:creator>
      <dc:creator>Owain R Edwards</dc:creator>
      <dc:creator>Claudia I Emerson</dc:creator>
      <dc:creator>Kevin Esvelt</dc:creator>
      <dc:creator>Sam Weiss Evans</dc:creator>
      <dc:creator>Robert M Friedman</dc:creator>
      <dc:creator>Valentino M Gantz</dc:creator>
      <dc:creator>Fred Gould</dc:creator>
      <dc:creator>Sarah Hartley</dc:creator>
      <dc:creator>Elizabeth Heitman</dc:creator>
      <dc:creator>Janet Hemingway</dc:creator>
      <dc:creator>Hirotaka Kanuka</dc:creator>
      <dc:creator>Jennifer Kuzma</dc:creator>
      <dc:creator>James V Lavery</dc:creator>
      <dc:creator>Yoosook Lee</dc:creator>
      <dc:creator>Marce Lorenzen</dc:creator>
      <dc:creator>Jeantine E Lunshof</dc:creator>
      <dc:creator>John M Marshall</dc:creator>
      <dc:creator>Philipp W Messer</dc:creator>
      <dc:creator>Craig Montell</dc:creator>
      <dc:creator>Kenneth A Oye</dc:creator>
      <dc:creator>Megan J Palmer</dc:creator>
      <dc:creator>Philippos Aris Papathanos</dc:creator>
      <dc:creator>Prasad N Paradkar</dc:creator>
      <dc:creator>Antoinette J Piaggio</dc:creator>
      <dc:creator>Jason L Rasgon</dc:creator>
      <dc:creator>Gordana Rašić</dc:creator>
      <dc:creator>Larisa Rudenko</dc:creator>
      <dc:creator>J Royden Saah</dc:creator>
      <dc:creator>Maxwell J Scott</dc:creator>
      <dc:creator>Jolene T Sutton</dc:creator>
      <dc:creator>Adam E Vorsino</dc:creator>
      <dc:creator>Omar S Akbari</dc:creator>
      <dc:date>2020-12-18</dc:date>
      <dc:source>Science (New York, N.Y.)</dc:source>
      <dc:title>Core commitments for field trials of gene drive organisms</dc:title>
      <dc:identifier>pmid:33335055</dc:identifier>
      <dc:identifier>doi:10.1126/science.abd1908</dc:identifier>
    </item>
    <item>
      <title>The biosecurity benefits of genetic engineering attribution</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33293537/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Biology can be misused, and the risk of this causing widespread harm increases in step with the rapid march of technological progress. A key security challenge involves attribution: determining, in the wake of a human-caused biological event, who was responsible. Recent scientific developments have demonstrated a capability for detecting whether an organism involved in such an event has been genetically modified and, if modified, to infer from its genetic sequence its likely lab of origin. We...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Commun. 2020 Dec 8;11(1):6294. doi: 10.1038/s41467-020-19149-2.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Biology can be misused, and the risk of this causing widespread harm increases in step with the rapid march of technological progress. A key security challenge involves attribution: determining, in the wake of a human-caused biological event, who was responsible. Recent scientific developments have demonstrated a capability for detecting whether an organism involved in such an event has been genetically modified and, if modified, to infer from its genetic sequence its likely lab of origin. We believe this technique could be developed into powerful forensic tools to aid the attribution of outbreaks caused by genetically engineered pathogens, and thus protect against the potential misuse of synthetic biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33293537/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33293537</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7722838/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7722838</a> | DOI:<a href=https://doi.org/10.1038/s41467-020-19149-2>10.1038/s41467-020-19149-2</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33293537</guid>
      <pubDate>Wed, 09 Dec 2020 06:00:00 -0500</pubDate>
      <dc:creator>Gregory Lewis</dc:creator>
      <dc:creator>Jacob L Jordan</dc:creator>
      <dc:creator>David A Relman</dc:creator>
      <dc:creator>Gregory D Koblentz</dc:creator>
      <dc:creator>Jade Leung</dc:creator>
      <dc:creator>Allan Dafoe</dc:creator>
      <dc:creator>Cassidy Nelson</dc:creator>
      <dc:creator>Gerald L Epstein</dc:creator>
      <dc:creator>Rebecca Katz</dc:creator>
      <dc:creator>Michael Montague</dc:creator>
      <dc:creator>Ethan C Alley</dc:creator>
      <dc:creator>Claire Marie Filone</dc:creator>
      <dc:creator>Stephen Luby</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Piers Millett</dc:creator>
      <dc:creator>Kevin M Esvelt</dc:creator>
      <dc:creator>Elizabeth E Cameron</dc:creator>
      <dc:creator>Thomas V Inglesby</dc:creator>
      <dc:date>2020-12-09</dc:date>
      <dc:source>Nature communications</dc:source>
      <dc:title>The biosecurity benefits of genetic engineering attribution</dc:title>
      <dc:identifier>pmid:33293537</dc:identifier>
      <dc:identifier>pmc:PMC7722838</dc:identifier>
      <dc:identifier>doi:10.1038/s41467-020-19149-2</dc:identifier>
    </item>
    <item>
      <title>A machine learning toolkit for genetic engineering attribution to facilitate biosecurity</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33293535/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The promise of biotechnology is tempered by its potential for accidental or deliberate misuse. Reliably identifying telltale signatures characteristic to different genetic designers, termed 'genetic engineering attribution', would deter misuse, yet is still considered unsolved. Here, we show that recurrent neural networks trained on DNA motifs and basic phenotype data can reach 70% attribution accuracy in distinguishing between over 1,300 labs. To make these models usable in practice, we...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Commun. 2020 Dec 8;11(1):6293. doi: 10.1038/s41467-020-19612-0.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The promise of biotechnology is tempered by its potential for accidental or deliberate misuse. Reliably identifying telltale signatures characteristic to different genetic designers, termed 'genetic engineering attribution', would deter misuse, yet is still considered unsolved. Here, we show that recurrent neural networks trained on DNA motifs and basic phenotype data can reach 70% attribution accuracy in distinguishing between over 1,300 labs. To make these models usable in practice, we introduce a framework for weighing predictions against other investigative evidence using calibration, and bring our model to within 1.6% of perfect calibration. Additionally, we demonstrate that simple models can accurately predict both the nation-state-of-origin and ancestor labs, forming the foundation of an integrated attribution toolkit which should promote responsible innovation and international security alike.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33293535/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33293535</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7722865/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7722865</a> | DOI:<a href=https://doi.org/10.1038/s41467-020-19612-0>10.1038/s41467-020-19612-0</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33293535</guid>
      <pubDate>Wed, 09 Dec 2020 06:00:00 -0500</pubDate>
      <dc:creator>Ethan C Alley</dc:creator>
      <dc:creator>Miles Turpin</dc:creator>
      <dc:creator>Andrew Bo Liu</dc:creator>
      <dc:creator>Taylor Kulp-McDowall</dc:creator>
      <dc:creator>Jacob Swett</dc:creator>
      <dc:creator>Rey Edison</dc:creator>
      <dc:creator>Stephen E Von Stetina</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Kevin M Esvelt</dc:creator>
      <dc:date>2020-12-09</dc:date>
      <dc:source>Nature communications</dc:source>
      <dc:title>A machine learning toolkit for genetic engineering attribution to facilitate biosecurity</dc:title>
      <dc:identifier>pmid:33293535</dc:identifier>
      <dc:identifier>pmc:PMC7722865</dc:identifier>
      <dc:identifier>doi:10.1038/s41467-020-19612-0</dc:identifier>
    </item>
    <item>
      <title>Chromosome-scale, haplotype-resolved assembly of human genomes</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33288905/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Haplotype-resolved or phased genome assembly provides a complete picture of genomes and their complex genetic variations. However, current algorithms for phased assembly either do not generate chromosome-scale phasing or require pedigree information, which limits their application. We present a method named diploid assembly (DipAsm) that uses long, accurate reads and long-range conformation data for single individuals to generate a chromosome-scale phased assembly within 1 day. Applied to four...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Biotechnol. 2021 Mar;39(3):309-312. doi: 10.1038/s41587-020-0711-0. Epub 2020 Dec 7.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Haplotype-resolved or phased genome assembly provides a complete picture of genomes and their complex genetic variations. However, current algorithms for phased assembly either do not generate chromosome-scale phasing or require pedigree information, which limits their application. We present a method named diploid assembly (DipAsm) that uses long, accurate reads and long-range conformation data for single individuals to generate a chromosome-scale phased assembly within 1 day. Applied to four public human genomes, PGP1, HG002, NA12878 and HG00733, DipAsm produced haplotype-resolved assemblies with minimum contig length needed to cover 50% of the known genome (NG50) up to 25 Mb and phased ~99.5% of heterozygous sites at 98-99% accuracy, outperforming other approaches in terms of both contiguity and phasing completeness. We demonstrate the importance of chromosome-scale phased assemblies for the discovery of structural variants (SVs), including thousands of new transposon insertions, and of highly polymorphic and medically important regions such as the human leukocyte antigen (HLA) and killer cell immunoglobulin-like receptor (KIR) regions. DipAsm will facilitate high-quality precision medicine and studies of individual haplotype variation and population diversity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33288905/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33288905</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7954703/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7954703</a> | DOI:<a href=https://doi.org/10.1038/s41587-020-0711-0>10.1038/s41587-020-0711-0</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33288905</guid>
      <pubDate>Tue, 08 Dec 2020 06:00:00 -0500</pubDate>
      <dc:creator>Shilpa Garg</dc:creator>
      <dc:creator>Arkarachai Fungtammasan</dc:creator>
      <dc:creator>Andrew Carroll</dc:creator>
      <dc:creator>Mike Chou</dc:creator>
      <dc:creator>Anthony Schmitt</dc:creator>
      <dc:creator>Xiang Zhou</dc:creator>
      <dc:creator>Stephen Mac</dc:creator>
      <dc:creator>Paul Peluso</dc:creator>
      <dc:creator>Emily Hatas</dc:creator>
      <dc:creator>Jay Ghurye</dc:creator>
      <dc:creator>Jared Maguire</dc:creator>
      <dc:creator>Medhat Mahmoud</dc:creator>
      <dc:creator>Haoyu Cheng</dc:creator>
      <dc:creator>David Heller</dc:creator>
      <dc:creator>Justin M Zook</dc:creator>
      <dc:creator>Tobias Moemke</dc:creator>
      <dc:creator>Tobias Marschall</dc:creator>
      <dc:creator>Fritz J Sedlazeck</dc:creator>
      <dc:creator>John Aach</dc:creator>
      <dc:creator>Chen-Shan Chin</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Heng Li</dc:creator>
      <dc:date>2020-12-08</dc:date>
      <dc:source>Nature biotechnology</dc:source>
      <dc:title>Chromosome-scale, haplotype-resolved assembly of human genomes</dc:title>
      <dc:identifier>pmid:33288905</dc:identifier>
      <dc:identifier>pmc:PMC7954703</dc:identifier>
      <dc:identifier>doi:10.1038/s41587-020-0711-0</dc:identifier>
    </item>
    <item>
      <title>Reprogramming to recover youthful epigenetic information and restore vision</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33268865/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Ageing is a degenerative process that leads to tissue dysfunction and death. A proposed cause of ageing is the accumulation of epigenetic noise that disrupts gene expression patterns, leading to decreases in tissue function and regenerative capacity^(1-3). Changes to DNA methylation patterns over time form the basis of ageing clocks⁴, but whether older individuals retain the information needed to restore these patterns-and, if so, whether this could improve tissue function-is not known. Over...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nature. 2020 Dec;588(7836):124-129. doi: 10.1038/s41586-020-2975-4. Epub 2020 Dec 2.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ageing is a degenerative process that leads to tissue dysfunction and death. A proposed cause of ageing is the accumulation of epigenetic noise that disrupts gene expression patterns, leading to decreases in tissue function and regenerative capacity<sup>1-3</sup>. Changes to DNA methylation patterns over time form the basis of ageing clocks<sup>4</sup>, but whether older individuals retain the information needed to restore these patterns-and, if so, whether this could improve tissue function-is not known. Over time, the central nervous system (CNS) loses function and regenerative capacity<sup>5-7</sup>. Using the eye as a model CNS tissue, here we show that ectopic expression of Oct4 (also known as Pou5f1), Sox2 and Klf4 genes (OSK) in mouse retinal ganglion cells restores youthful DNA methylation patterns and transcriptomes, promotes axon regeneration after injury, and reverses vision loss in a mouse model of glaucoma and in aged mice. The beneficial effects of OSK-induced reprogramming in axon regeneration and vision require the DNA demethylases TET1 and TET2. These data indicate that mammalian tissues retain a record of youthful epigenetic information-encoded in part by DNA methylation-that can be accessed to improve tissue function and promote regeneration in vivo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33268865/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33268865</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7752134/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7752134</a> | DOI:<a href=https://doi.org/10.1038/s41586-020-2975-4>10.1038/s41586-020-2975-4</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33268865</guid>
      <pubDate>Thu, 03 Dec 2020 06:00:00 -0500</pubDate>
      <dc:creator>Yuancheng Lu</dc:creator>
      <dc:creator>Benedikt Brommer</dc:creator>
      <dc:creator>Xiao Tian</dc:creator>
      <dc:creator>Anitha Krishnan</dc:creator>
      <dc:creator>Margarita Meer</dc:creator>
      <dc:creator>Chen Wang</dc:creator>
      <dc:creator>Daniel L Vera</dc:creator>
      <dc:creator>Qiurui Zeng</dc:creator>
      <dc:creator>Doudou Yu</dc:creator>
      <dc:creator>Michael S Bonkowski</dc:creator>
      <dc:creator>Jae-Hyun Yang</dc:creator>
      <dc:creator>Songlin Zhou</dc:creator>
      <dc:creator>Emma M Hoffmann</dc:creator>
      <dc:creator>Margarete M Karg</dc:creator>
      <dc:creator>Michael B Schultz</dc:creator>
      <dc:creator>Alice E Kane</dc:creator>
      <dc:creator>Noah Davidsohn</dc:creator>
      <dc:creator>Ekaterina Korobkina</dc:creator>
      <dc:creator>Karolina Chwalek</dc:creator>
      <dc:creator>Luis A Rajman</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Konrad Hochedlinger</dc:creator>
      <dc:creator>Vadim N Gladyshev</dc:creator>
      <dc:creator>Steve Horvath</dc:creator>
      <dc:creator>Morgan E Levine</dc:creator>
      <dc:creator>Meredith S Gregory-Ksander</dc:creator>
      <dc:creator>Bruce R Ksander</dc:creator>
      <dc:creator>Zhigang He</dc:creator>
      <dc:creator>David A Sinclair</dc:creator>
      <dc:date>2020-12-03</dc:date>
      <dc:source>Nature</dc:source>
      <dc:title>Reprogramming to recover youthful epigenetic information and restore vision</dc:title>
      <dc:identifier>pmid:33268865</dc:identifier>
      <dc:identifier>pmc:PMC7752134</dc:identifier>
      <dc:identifier>doi:10.1038/s41586-020-2975-4</dc:identifier>
    </item>
    <item>
      <title>A comprehensive library of human transcription factors for cell fate engineering</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33257861/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Human pluripotent stem cells (hPSCs) offer an unprecedented opportunity to model diverse cell types and tissues. To enable systematic exploration of the programming landscape mediated by transcription factors (TFs), we present the Human TFome, a comprehensive library containing 1,564 TF genes and 1,732 TF splice isoforms. By screening the library in three hPSC lines, we discovered 290 TFs, including 241 that were previously unreported, that induce differentiation in 4 days without alteration of...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Biotechnol. 2021 Apr;39(4):510-519. doi: 10.1038/s41587-020-0742-6. Epub 2020 Nov 30.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human pluripotent stem cells (hPSCs) offer an unprecedented opportunity to model diverse cell types and tissues. To enable systematic exploration of the programming landscape mediated by transcription factors (TFs), we present the Human TFome, a comprehensive library containing 1,564 TF genes and 1,732 TF splice isoforms. By screening the library in three hPSC lines, we discovered 290 TFs, including 241 that were previously unreported, that induce differentiation in 4 days without alteration of external soluble or biomechanical cues. We used four of the hits to program hPSCs into neurons, fibroblasts, oligodendrocytes and vascular endothelial-like cells that have molecular and functional similarity to primary cells. Our cell-autonomous approach enabled parallel programming of hPSCs into multiple cell types simultaneously. We also demonstrated orthogonal programming by including oligodendrocyte-inducible hPSCs with unmodified hPSCs to generate cerebral organoids, which expedited in situ myelination. Large-scale combinatorial screening of the Human TFome will complement other strategies for cell engineering based on developmental biology and computational systems biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33257861/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33257861</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7610615/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7610615</a> | DOI:<a href=https://doi.org/10.1038/s41587-020-0742-6>10.1038/s41587-020-0742-6</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33257861</guid>
      <pubDate>Tue, 01 Dec 2020 06:00:00 -0500</pubDate>
      <dc:creator>Alex H M Ng</dc:creator>
      <dc:creator>Parastoo Khoshakhlagh</dc:creator>
      <dc:creator>Jesus Eduardo Rojo Arias</dc:creator>
      <dc:creator>Giovanni Pasquini</dc:creator>
      <dc:creator>Kai Wang</dc:creator>
      <dc:creator>Anka Swiersy</dc:creator>
      <dc:creator>Seth L Shipman</dc:creator>
      <dc:creator>Evan Appleton</dc:creator>
      <dc:creator>Kiavash Kiaee</dc:creator>
      <dc:creator>Richie E Kohman</dc:creator>
      <dc:creator>Andyna Vernet</dc:creator>
      <dc:creator>Matthew Dysart</dc:creator>
      <dc:creator>Kathleen Leeper</dc:creator>
      <dc:creator>Wren Saylor</dc:creator>
      <dc:creator>Jeremy Y Huang</dc:creator>
      <dc:creator>Amanda Graveline</dc:creator>
      <dc:creator>Jussi Taipale</dc:creator>
      <dc:creator>David E Hill</dc:creator>
      <dc:creator>Marc Vidal</dc:creator>
      <dc:creator>Juan M Melero-Martin</dc:creator>
      <dc:creator>Volker Busskamp</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2020-12-01</dc:date>
      <dc:source>Nature biotechnology</dc:source>
      <dc:title>A comprehensive library of human transcription factors for cell fate engineering</dc:title>
      <dc:identifier>pmid:33257861</dc:identifier>
      <dc:identifier>pmc:PMC7610615</dc:identifier>
      <dc:identifier>doi:10.1038/s41587-020-0742-6</dc:identifier>
    </item>
    <item>
      <title>Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33230174/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has elicited a global health crisis of catastrophic proportions. With only a few vaccines approved for early or limited use, there is a critical need for effective antiviral strategies. In this study, we report a unique antiviral platform, through computational design of ACE2-derived peptides which both target the viral spike protein receptor binding domain (RBD) and recruit E3 ubiquitin ligases for subsequent intracellular...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Commun Biol. 2020 Nov 23;3(1):715. doi: 10.1038/s42003-020-01470-7.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has elicited a global health crisis of catastrophic proportions. With only a few vaccines approved for early or limited use, there is a critical need for effective antiviral strategies. In this study, we report a unique antiviral platform, through computational design of ACE2-derived peptides which both target the viral spike protein receptor binding domain (RBD) and recruit E3 ubiquitin ligases for subsequent intracellular degradation of SARS-CoV-2 in the proteasome. Our engineered peptide fusions demonstrate robust RBD degradation capabilities in human cells and are capable of inhibiting infection-competent viral production, thus prompting their further experimental characterization and therapeutic development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33230174/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33230174</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7683566/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7683566</a> | DOI:<a href=https://doi.org/10.1038/s42003-020-01470-7>10.1038/s42003-020-01470-7</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33230174</guid>
      <pubDate>Tue, 24 Nov 2020 06:00:00 -0500</pubDate>
      <dc:creator>Pranam Chatterjee</dc:creator>
      <dc:creator>Manvitha Ponnapati</dc:creator>
      <dc:creator>Christian Kramme</dc:creator>
      <dc:creator>Alexandru M Plesa</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Joseph M Jacobson</dc:creator>
      <dc:date>2020-11-24</dc:date>
      <dc:source>Communications biology</dc:source>
      <dc:title>Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions</dc:title>
      <dc:identifier>pmid:33230174</dc:identifier>
      <dc:identifier>pmc:PMC7683566</dc:identifier>
      <dc:identifier>doi:10.1038/s42003-020-01470-7</dc:identifier>
    </item>
    <item>
      <title>Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33176869/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The Chimera antigen receptor (CAR)-T cell therapy has gained great success in the clinic. However, there are still major challenges for its wider applications in a variety of cancer types including lack of effectiveness due to the highly complex tumor microenvironment, and the forbiddingly high cost due to the personalized manufacturing procedures. In order to overcome these hurdles, numerous efforts have been spent focusing on optimizing Chimera antigen receptors, engineering and improving T...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">J Hematol Oncol. 2020 Nov 11;13(1):153. doi: 10.1186/s13045-020-00983-2.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The Chimera antigen receptor (CAR)-T cell therapy has gained great success in the clinic. However, there are still major challenges for its wider applications in a variety of cancer types including lack of effectiveness due to the highly complex tumor microenvironment, and the forbiddingly high cost due to the personalized manufacturing procedures. In order to overcome these hurdles, numerous efforts have been spent focusing on optimizing Chimera antigen receptors, engineering and improving T cell capacity, exploiting features of subsets of T cell or NK cells, or making off-the-shelf universal cells. Here, we developed induced pluripotent stem cells (iPSCs)-derived, CAR-expressing macrophage cells (CAR-iMac). CAR expression confers antigen-dependent macrophage functions such as expression and secretion of cytokines, polarization toward the pro-inflammatory/anti-tumor state, enhanced phagocytosis of tumor cells, and in vivo anticancer cell activity. This technology platform for the first time provides an unlimited source of iPSC-derived engineered CAR-macrophage cells which could be utilized to eliminate cancer cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33176869/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33176869</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7656711/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7656711</a> | DOI:<a href=https://doi.org/10.1186/s13045-020-00983-2>10.1186/s13045-020-00983-2</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33176869</guid>
      <pubDate>Thu, 12 Nov 2020 06:00:00 -0500</pubDate>
      <dc:creator>Li Zhang</dc:creator>
      <dc:creator>Lin Tian</dc:creator>
      <dc:creator>Xiaoyang Dai</dc:creator>
      <dc:creator>Hua Yu</dc:creator>
      <dc:creator>Jiajia Wang</dc:creator>
      <dc:creator>Anhua Lei</dc:creator>
      <dc:creator>Mengmeng Zhu</dc:creator>
      <dc:creator>Jianpo Xu</dc:creator>
      <dc:creator>Wei Zhao</dc:creator>
      <dc:creator>Yuqing Zhu</dc:creator>
      <dc:creator>Zhen Sun</dc:creator>
      <dc:creator>Hao Zhang</dc:creator>
      <dc:creator>Yongxian Hu</dc:creator>
      <dc:creator>Yanlin Wang</dc:creator>
      <dc:creator>Yuming Xu</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>He Huang</dc:creator>
      <dc:creator>Qinjie Weng</dc:creator>
      <dc:creator>Jin Zhang</dc:creator>
      <dc:date>2020-11-12</dc:date>
      <dc:source>Journal of hematology &amp; oncology</dc:source>
      <dc:title>Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions</dc:title>
      <dc:identifier>pmid:33176869</dc:identifier>
      <dc:identifier>pmc:PMC7656711</dc:identifier>
      <dc:identifier>doi:10.1186/s13045-020-00983-2</dc:identifier>
    </item>
    <item>
      <title>Reactions to the National Academies/Royal Society Report on &lt;em&gt;Heritable Human Genome Editing&lt;/em&gt;</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33095048/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>In September 2020, a detailed report on Heritable Human Genome Editing was published. The report offers a translational pathway for the limited approval of germline editing under limited circumstances and assuming various criteria have been met. In this perspective, some three dozen experts from the fields of genome editing, medicine, bioethics, law, and related fields offer their candid reactions to the National Academies/Royal Society report, highlighting areas of support, omissions,...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">CRISPR J. 2020 Oct;3(5):332-349. doi: 10.1089/crispr.2020.29106.man.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In September 2020, a detailed report on <i>Heritable Human Genome Editing</i> was published. The report offers a translational pathway for the limited approval of germline editing under limited circumstances and assuming various criteria have been met. In this perspective, some three dozen experts from the fields of genome editing, medicine, bioethics, law, and related fields offer their candid reactions to the National Academies/Royal Society report, highlighting areas of support, omissions, disagreements, and priorities moving forward.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33095048/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33095048</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC8935482/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC8935482</a> | DOI:<a href=https://doi.org/10.1089/crispr.2020.29106.man>10.1089/crispr.2020.29106.man</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33095048</guid>
      <pubDate>Fri, 23 Oct 2020 06:00:00 -0400</pubDate>
      <dc:creator>Misha Angrist</dc:creator>
      <dc:creator>Rodolphe Barrangou</dc:creator>
      <dc:creator>Françoise Baylis</dc:creator>
      <dc:creator>Carolyn Brokowski</dc:creator>
      <dc:creator>Gaetan Burgio</dc:creator>
      <dc:creator>Arthur Caplan</dc:creator>
      <dc:creator>Carolyn Riley Chapman</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Robert Cook-Deegan</dc:creator>
      <dc:creator>Bryan Cwik</dc:creator>
      <dc:creator>Jennifer A Doudna</dc:creator>
      <dc:creator>John H Evans</dc:creator>
      <dc:creator>Henry T Greely</dc:creator>
      <dc:creator>Laura Hercher</dc:creator>
      <dc:creator>J Benjamin Hurlbut</dc:creator>
      <dc:creator>Richard O Hynes</dc:creator>
      <dc:creator>Tetsuya Ishii</dc:creator>
      <dc:creator>Samira Kiani</dc:creator>
      <dc:creator>LaTasha Hoskins Lee</dc:creator>
      <dc:creator>Guillaume Levrier</dc:creator>
      <dc:creator>David R Liu</dc:creator>
      <dc:creator>Jeantine E Lunshof</dc:creator>
      <dc:creator>Kerry Lynn Macintosh</dc:creator>
      <dc:creator>Debra J H Mathews</dc:creator>
      <dc:creator>Eric M Meslin</dc:creator>
      <dc:creator>Peter H R Mills</dc:creator>
      <dc:creator>Lluis Montoliu</dc:creator>
      <dc:creator>Kiran Musunuru</dc:creator>
      <dc:creator>Dianne Nicol</dc:creator>
      <dc:creator>Helen O'Neill</dc:creator>
      <dc:creator>Renzong Qiu</dc:creator>
      <dc:creator>Robert Ranisch</dc:creator>
      <dc:creator>Jacob S Sherkow</dc:creator>
      <dc:creator>Sheetal Soni</dc:creator>
      <dc:creator>Sharon Terry</dc:creator>
      <dc:creator>Eric Topol</dc:creator>
      <dc:creator>Robert Williamson</dc:creator>
      <dc:creator>Feng Zhang</dc:creator>
      <dc:creator>Kevin Davies</dc:creator>
      <dc:date>2020-10-23</dc:date>
      <dc:source>The CRISPR journal</dc:source>
      <dc:title>Reactions to the National Academies/Royal Society Report on &lt;em&gt;Heritable Human Genome Editing&lt;/em&gt;</dc:title>
      <dc:identifier>pmid:33095048</dc:identifier>
      <dc:identifier>pmc:PMC8935482</dc:identifier>
      <dc:identifier>doi:10.1089/crispr.2020.29106.man</dc:identifier>
    </item>
    <item>
      <title>Photon-directed multiplexed enzymatic DNA synthesis for molecular digital data storage</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33067441/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>New storage technologies are needed to keep up with the global demands of data generation. DNA is an ideal storage medium due to its stability, information density and ease-of-readout with advanced sequencing techniques. However, progress in writing DNA is stifled by the continued reliance on chemical synthesis methods. The enzymatic synthesis of DNA is a promising alternative, but thus far has not been well demonstrated in a parallelized manner. Here, we report a multiplexed enzymatic DNA...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Commun. 2020 Oct 16;11(1):5246. doi: 10.1038/s41467-020-18681-5.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">New storage technologies are needed to keep up with the global demands of data generation. DNA is an ideal storage medium due to its stability, information density and ease-of-readout with advanced sequencing techniques. However, progress in writing DNA is stifled by the continued reliance on chemical synthesis methods. The enzymatic synthesis of DNA is a promising alternative, but thus far has not been well demonstrated in a parallelized manner. Here, we report a multiplexed enzymatic DNA synthesis method using maskless photolithography. Rapid uncaging of Co<sup>2+</sup> ions by patterned UV light activates Terminal deoxynucleotidyl Transferase (TdT) for spatially-selective synthesis on an array surface. Spontaneous quenching of reactions by the diffusion of excess caging molecules confines synthesis to light patterns and controls the extension length. We show that our multiplexed synthesis method can be used to store digital data by encoding 12 unique DNA oligonucleotide sequences with video game music, which is equivalent to 84 trits or 110 bits of data.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33067441/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33067441</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7567835/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7567835</a> | DOI:<a href=https://doi.org/10.1038/s41467-020-18681-5>10.1038/s41467-020-18681-5</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33067441</guid>
      <pubDate>Sat, 17 Oct 2020 06:00:00 -0400</pubDate>
      <dc:creator>Howon Lee</dc:creator>
      <dc:creator>Daniel J Wiegand</dc:creator>
      <dc:creator>Kettner Griswold</dc:creator>
      <dc:creator>Sukanya Punthambaker</dc:creator>
      <dc:creator>Honggu Chun</dc:creator>
      <dc:creator>Richie E Kohman</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2020-10-17</dc:date>
      <dc:source>Nature communications</dc:source>
      <dc:title>Photon-directed multiplexed enzymatic DNA synthesis for molecular digital data storage</dc:title>
      <dc:identifier>pmid:33067441</dc:identifier>
      <dc:identifier>pmc:PMC7567835</dc:identifier>
      <dc:identifier>doi:10.1038/s41467-020-18681-5</dc:identifier>
    </item>
    <item>
      <title>Benchmarking evolutionary tinkering underlying human-viral molecular mimicry shows multiple host pulmonary-arterial peptides mimicked by SARS-CoV-2</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/33024578/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The hand of molecular mimicry in shaping SARS-CoV-2 evolution and immune evasion remains to be deciphered. Here, we report 33 distinct 8-mer/9-mer peptides that are identical between SARS-CoV-2 and the human reference proteome. We benchmark this observation against other viral-human 8-mer/9-mer peptide identity, which suggests generally similar extents of molecular mimicry for SARS-CoV-2 and many other human viruses. Interestingly, 20 novel human peptides mimicked by SARS-CoV-2 have not been...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Cell Death Discov. 2020 Oct 2;6(1):96. doi: 10.1038/s41420-020-00321-y. eCollection 2020.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The hand of molecular mimicry in shaping SARS-CoV-2 evolution and immune evasion remains to be deciphered. Here, we report 33 distinct 8-mer/9-mer peptides that are identical between SARS-CoV-2 and the human reference proteome. We benchmark this observation against other viral-human 8-mer/9-mer peptide identity, which suggests generally similar extents of molecular mimicry for SARS-CoV-2 and many other human viruses. Interestingly, 20 novel human peptides mimicked by SARS-CoV-2 have not been observed in any previous coronavirus strains (HCoV, SARS-CoV, and MERS). Furthermore, four of the human 8-mer/9-mer peptides mimicked by SARS-CoV-2 map onto HLA-B*40:01, HLA-B*40:02, and HLA-B*35:01 binding peptides from human PAM, ANXA7, PGD, and ALOX5AP proteins. This mimicry of multiple human proteins by SARS-CoV-2 is made salient by single-cell RNA-seq (scRNA-seq) analysis that shows the targeted genes significantly expressed in human lungs and arteries; tissues implicated in COVID-19 pathogenesis. Finally, HLA-A*03 restricted 8-mer peptides are found to be shared broadly by human and coronaviridae helicases in functional hotspots, with potential implications for nucleic acid unwinding upon initial infection. This study presents the first scan of human peptide mimicry by SARS-CoV-2, and via its benchmarking against human-viral mimicry more broadly, presents a computational framework for follow-up studies to assay how evolutionary tinkering may relate to zoonosis and herd immunity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/33024578/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">33024578</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7529588/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7529588</a> | DOI:<a href=https://doi.org/10.1038/s41420-020-00321-y>10.1038/s41420-020-00321-y</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:33024578</guid>
      <pubDate>Wed, 07 Oct 2020 06:00:00 -0400</pubDate>
      <dc:creator>A J Venkatakrishnan</dc:creator>
      <dc:creator>Nikhil Kayal</dc:creator>
      <dc:creator>Praveen Anand</dc:creator>
      <dc:creator>Andrew D Badley</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Venky Soundararajan</dc:creator>
      <dc:date>2020-10-07</dc:date>
      <dc:source>Cell death discovery</dc:source>
      <dc:title>Benchmarking evolutionary tinkering underlying human-viral molecular mimicry shows multiple host pulmonary-arterial peptides mimicked by SARS-CoV-2</dc:title>
      <dc:identifier>pmid:33024578</dc:identifier>
      <dc:identifier>pmc:PMC7529588</dc:identifier>
      <dc:identifier>doi:10.1038/s41420-020-00321-y</dc:identifier>
    </item>
    <item>
      <title>Extensive germline genome engineering in pigs</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/32958897/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The clinical applicability of porcine xenotransplantation-a long-investigated alternative to the scarce availability of human organs for patients with organ failure-is limited by molecular incompatibilities between the immune systems of pigs and humans as well as by the risk of transmitting porcine endogenous retroviruses (PERVs). We recently showed the production of pigs with genomically inactivated PERVs. Here, using a combination of CRISPR-Cas9 and transposon technologies, we show that pigs...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Biomed Eng. 2021 Feb;5(2):134-143. doi: 10.1038/s41551-020-00613-9. Epub 2020 Sep 21.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The clinical applicability of porcine xenotransplantation-a long-investigated alternative to the scarce availability of human organs for patients with organ failure-is limited by molecular incompatibilities between the immune systems of pigs and humans as well as by the risk of transmitting porcine endogenous retroviruses (PERVs). We recently showed the production of pigs with genomically inactivated PERVs. Here, using a combination of CRISPR-Cas9 and transposon technologies, we show that pigs with all PERVs inactivated can also be genetically engineered to eliminate three xenoantigens and to express nine human transgenes that enhance the pigs' immunological compatibility and blood-coagulation compatibility with humans. The engineered pigs exhibit normal physiology, fertility and germline transmission of the 13 genes and 42 alleles edited. Using in vitro assays, we show that cells from the engineered pigs are resistant to human humoral rejection, cell-mediated damage and pathogenesis associated with dysregulated coagulation. The extensive genome engineering of pigs for greater compatibility with the human immune system may eventually enable safe and effective porcine xenotransplantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/32958897/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">32958897</a> | DOI:<a href=https://doi.org/10.1038/s41551-020-00613-9>10.1038/s41551-020-00613-9</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:32958897</guid>
      <pubDate>Tue, 22 Sep 2020 06:00:00 -0400</pubDate>
      <dc:creator>Yanan Yue</dc:creator>
      <dc:creator>Weihong Xu</dc:creator>
      <dc:creator>Yinan Kan</dc:creator>
      <dc:creator>Hong-Ye Zhao</dc:creator>
      <dc:creator>Yixuan Zhou</dc:creator>
      <dc:creator>Xiaobin Song</dc:creator>
      <dc:creator>Jiajia Wu</dc:creator>
      <dc:creator>Juan Xiong</dc:creator>
      <dc:creator>Dharmendra Goswami</dc:creator>
      <dc:creator>Meng Yang</dc:creator>
      <dc:creator>Lydia Lamriben</dc:creator>
      <dc:creator>Mengyuan Xu</dc:creator>
      <dc:creator>Qi Zhang</dc:creator>
      <dc:creator>Yu Luo</dc:creator>
      <dc:creator>Jianxiong Guo</dc:creator>
      <dc:creator>Shengyi Mao</dc:creator>
      <dc:creator>Deling Jiao</dc:creator>
      <dc:creator>Tien Dat Nguyen</dc:creator>
      <dc:creator>Zhuo Li</dc:creator>
      <dc:creator>Jacob V Layer</dc:creator>
      <dc:creator>Mailin Li</dc:creator>
      <dc:creator>Violette Paragas</dc:creator>
      <dc:creator>Michele E Youd</dc:creator>
      <dc:creator>Zhongquan Sun</dc:creator>
      <dc:creator>Yuan Ding</dc:creator>
      <dc:creator>Weilin Wang</dc:creator>
      <dc:creator>Hongwei Dou</dc:creator>
      <dc:creator>Lingling Song</dc:creator>
      <dc:creator>Xueqiong Wang</dc:creator>
      <dc:creator>Lei Le</dc:creator>
      <dc:creator>Xin Fang</dc:creator>
      <dc:creator>Haydy George</dc:creator>
      <dc:creator>Ranjith Anand</dc:creator>
      <dc:creator>Shi Yun Wang</dc:creator>
      <dc:creator>William F Westlin</dc:creator>
      <dc:creator>Marc Güell</dc:creator>
      <dc:creator>James Markmann</dc:creator>
      <dc:creator>Wenning Qin</dc:creator>
      <dc:creator>Yangbin Gao</dc:creator>
      <dc:creator>Hong-Jiang Wei</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Luhan Yang</dc:creator>
      <dc:date>2020-09-22</dc:date>
      <dc:source>Nature biomedical engineering</dc:source>
      <dc:title>Extensive germline genome engineering in pigs</dc:title>
      <dc:identifier>pmid:32958897</dc:identifier>
      <dc:identifier>doi:10.1038/s41551-020-00613-9</dc:identifier>
    </item>
    <item>
      <title>TBDB: a database of structurally annotated T-box riboswitch:tRNA pairs</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/32882008/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>T-box riboswitches constitute a large family of tRNA-binding leader sequences that play a central role in gene regulation in many gram-positive bacteria. Accurate inference of the tRNA binding to T-box riboswitches is critical to predict their cis-regulatory activity. However, there is no central repository of information on the tRNA binding specificities of T-box riboswitches, and de novo prediction of binding specificities requires advanced knowledge of computational tools to annotate...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nucleic Acids Res. 2021 Jan 8;49(D1):D229-D235. doi: 10.1093/nar/gkaa721.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">T-box riboswitches constitute a large family of tRNA-binding leader sequences that play a central role in gene regulation in many gram-positive bacteria. Accurate inference of the tRNA binding to T-box riboswitches is critical to predict their cis-regulatory activity. However, there is no central repository of information on the tRNA binding specificities of T-box riboswitches, and de novo prediction of binding specificities requires advanced knowledge of computational tools to annotate riboswitch secondary structure features. Here, we present the T-box Riboswitch Annotation Database (TBDB, https://tbdb.io), an open-access database with a collection of 23,535 T-box riboswitch sequences, spanning the major phyla of 3,632 bacterial species. Among structural predictions, the TBDB also identifies specifier sequences, cognate tRNA binding partners, and downstream regulatory targets. To our knowledge, the TBDB presents the largest collection of feature, sequence, and structural annotations carried out on this important family of regulatory RNA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/32882008/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">32882008</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7778990/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7778990</a> | DOI:<a href=https://doi.org/10.1093/nar/gkaa721>10.1093/nar/gkaa721</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:32882008</guid>
      <pubDate>Fri, 04 Sep 2020 06:00:00 -0400</pubDate>
      <dc:creator>Jorge A Marchand</dc:creator>
      <dc:creator>Merrick D Pierson Smela</dc:creator>
      <dc:creator>Thomas H H Jordan</dc:creator>
      <dc:creator>Kamesh Narasimhan</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2020-09-04</dc:date>
      <dc:source>Nucleic acids research</dc:source>
      <dc:title>TBDB: a database of structurally annotated T-box riboswitch:tRNA pairs</dc:title>
      <dc:identifier>pmid:32882008</dc:identifier>
      <dc:identifier>pmc:PMC7778990</dc:identifier>
      <dc:identifier>doi:10.1093/nar/gkaa721</dc:identifier>
    </item>
    <item>
      <title>Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/32832668/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>Human induced pluripotent stem cell (h-iPSC)-derived endothelial cells (h-iECs) have become a valuable tool in regenerative medicine. However, current differentiation protocols remain inefficient and lack reliability. Here, we describe a method for rapid, consistent, and highly efficient generation of h-iECs. The protocol entails the delivery of modified mRNA encoding the transcription factor ETV2 at the intermediate mesodermal stage of differentiation. This approach reproducibly differentiated...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Sci Adv. 2020 Jul 24;6(30):eaba7606. doi: 10.1126/sciadv.aba7606. eCollection 2020 Jul.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human induced pluripotent stem cell (h-iPSC)-derived endothelial cells (h-iECs) have become a valuable tool in regenerative medicine. However, current differentiation protocols remain inefficient and lack reliability. Here, we describe a method for rapid, consistent, and highly efficient generation of h-iECs. The protocol entails the delivery of modified mRNA encoding the transcription factor <i>ETV2</i> at the intermediate mesodermal stage of differentiation. This approach reproducibly differentiated 13 diverse h-iPSC lines into h-iECs with exceedingly high efficiency. In contrast, standard differentiation methods that relied on endogenous <i>ETV2</i> were inefficient and notably inconsistent. Our h-iECs were functionally competent in many respects, including the ability to form perfused vascular networks in vivo. Timely activation of <i>ETV2</i> was critical, and bypassing the mesodermal stage produced putative h-iECs with reduced expansion potential and inability to form functional vessels. Our protocol has broad applications and could reliably provide an unlimited number of h-iECs for vascular therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/32832668/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">32832668</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7439318/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7439318</a> | DOI:<a href=https://doi.org/10.1126/sciadv.aba7606>10.1126/sciadv.aba7606</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:32832668</guid>
      <pubDate>Tue, 25 Aug 2020 06:00:00 -0400</pubDate>
      <dc:creator>Kai Wang</dc:creator>
      <dc:creator>Ruei-Zeng Lin</dc:creator>
      <dc:creator>Xuechong Hong</dc:creator>
      <dc:creator>Alex H Ng</dc:creator>
      <dc:creator>Chin Nien Lee</dc:creator>
      <dc:creator>Joseph Neumeyer</dc:creator>
      <dc:creator>Gang Wang</dc:creator>
      <dc:creator>Xi Wang</dc:creator>
      <dc:creator>Minglin Ma</dc:creator>
      <dc:creator>William T Pu</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Juan M Melero-Martin</dc:creator>
      <dc:date>2020-08-25</dc:date>
      <dc:source>Science advances</dc:source>
      <dc:title>Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA</dc:title>
      <dc:identifier>pmid:32832668</dc:identifier>
      <dc:identifier>pmc:PMC7439318</dc:identifier>
      <dc:identifier>doi:10.1126/sciadv.aba7606</dc:identifier>
    </item>
    <item>
      <title>The whale shark genome reveals how genomic and physiological properties scale with body size</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/32753383/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>The endangered whale shark (Rhincodon typus) is the largest fish on Earth and a long-lived member of the ancient Elasmobranchii clade. To characterize the relationship between genome features and biological traits, we sequenced and assembled the genome of the whale shark and compared its genomic and physiological features to those of 83 animals and yeast. We examined the scaling relationships between body size, temperature, metabolic rates, and genomic features and found both general...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20662-20671. doi: 10.1073/pnas.1922576117. Epub 2020 Aug 4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The endangered whale shark (<i>Rhincodon typus</i>) is the largest fish on Earth and a long-lived member of the ancient Elasmobranchii clade. To characterize the relationship between genome features and biological traits, we sequenced and assembled the genome of the whale shark and compared its genomic and physiological features to those of 83 animals and yeast. We examined the scaling relationships between body size, temperature, metabolic rates, and genomic features and found both general correlations across the animal kingdom and features specific to the whale shark genome. Among animals, increased lifespan is positively correlated to body size and metabolic rate. Several genomic traits also significantly correlated with body size, including intron and gene length. Our large-scale comparative genomic analysis uncovered general features of metazoan genome architecture: Guanine and cytosine (GC) content and codon adaptation index are negatively correlated, and neural connectivity genes are longer than average genes in most genomes. Focusing on the whale shark genome, we identified multiple features that significantly correlate with lifespan. Among these were very long gene length, due to introns being highly enriched in repetitive elements such as CR1-like long interspersed nuclear elements, and considerably longer neural genes of several types, including connectivity, activity, and neurodegeneration genes. The whale shark genome also has the second slowest evolutionary rate observed in vertebrates to date. Our comparative genomics approach uncovered multiple genetic features associated with body size, metabolic rate, and lifespan and showed that the whale shark is a promising model for studies of neural architecture and lifespan.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/32753383/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">32753383</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7456109/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7456109</a> | DOI:<a href=https://doi.org/10.1073/pnas.1922576117>10.1073/pnas.1922576117</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:32753383</guid>
      <pubDate>Thu, 06 Aug 2020 06:00:00 -0400</pubDate>
      <dc:creator>Jessica A Weber</dc:creator>
      <dc:creator>Seung Gu Park</dc:creator>
      <dc:creator>Victor Luria</dc:creator>
      <dc:creator>Sungwon Jeon</dc:creator>
      <dc:creator>Hak-Min Kim</dc:creator>
      <dc:creator>Yeonsu Jeon</dc:creator>
      <dc:creator>Youngjune Bhak</dc:creator>
      <dc:creator>Je Hun Jun</dc:creator>
      <dc:creator>Sang Wha Kim</dc:creator>
      <dc:creator>Won Hee Hong</dc:creator>
      <dc:creator>Semin Lee</dc:creator>
      <dc:creator>Yun Sung Cho</dc:creator>
      <dc:creator>Amir Karger</dc:creator>
      <dc:creator>John W Cain</dc:creator>
      <dc:creator>Andrea Manica</dc:creator>
      <dc:creator>Soonok Kim</dc:creator>
      <dc:creator>Jae-Hoon Kim</dc:creator>
      <dc:creator>Jeremy S Edwards</dc:creator>
      <dc:creator>Jong Bhak</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:date>2020-08-06</dc:date>
      <dc:source>Proceedings of the National Academy of Sciences of the United States of America</dc:source>
      <dc:title>The whale shark genome reveals how genomic and physiological properties scale with body size</dc:title>
      <dc:identifier>pmid:32753383</dc:identifier>
      <dc:identifier>pmc:PMC7456109</dc:identifier>
      <dc:identifier>doi:10.1073/pnas.1922576117</dc:identifier>
    </item>
    <item>
      <title>3D mapping and accelerated super-resolution imaging of the human genome using in situ sequencing</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/32719531/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>There is a need for methods that can image chromosomes with genome-wide coverage, as well as greater genomic and optical resolution. We introduce OligoFISSEQ, a suite of three methods that leverage fluorescence in situ sequencing (FISSEQ) of barcoded Oligopaint probes to enable the rapid visualization of many targeted genomic regions. Applying OligoFISSEQ to human diploid fibroblast cells, we show how four rounds of sequencing are sufficient to produce 3D maps of 36 genomic targets across six...</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Methods. 2020 Aug;17(8):822-832. doi: 10.1038/s41592-020-0890-0. Epub 2020 Jul 27.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There is a need for methods that can image chromosomes with genome-wide coverage, as well as greater genomic and optical resolution. We introduce OligoFISSEQ, a suite of three methods that leverage fluorescence in situ sequencing (FISSEQ) of barcoded Oligopaint probes to enable the rapid visualization of many targeted genomic regions. Applying OligoFISSEQ to human diploid fibroblast cells, we show how four rounds of sequencing are sufficient to produce 3D maps of 36 genomic targets across six chromosomes in hundreds to thousands of cells, implying a potential to image thousands of targets in only five to eight rounds of sequencing. We also use OligoFISSEQ to trace chromosomes at finer resolution, following the path of the X chromosome through 46 regions, with separate studies showing compatibility of OligoFISSEQ with immunocytochemistry. Finally, we combined OligoFISSEQ with OligoSTORM, laying the foundation for accelerated single-molecule super-resolution imaging of large swaths of, if not entire, human genomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/32719531/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">32719531</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC7537785/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">PMC7537785</a> | DOI:<a href=https://doi.org/10.1038/s41592-020-0890-0>10.1038/s41592-020-0890-0</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:32719531</guid>
      <pubDate>Wed, 29 Jul 2020 06:00:00 -0400</pubDate>
      <dc:creator>Huy Q Nguyen</dc:creator>
      <dc:creator>Shyamtanu Chattoraj</dc:creator>
      <dc:creator>David Castillo</dc:creator>
      <dc:creator>Son C Nguyen</dc:creator>
      <dc:creator>Guy Nir</dc:creator>
      <dc:creator>Antonios Lioutas</dc:creator>
      <dc:creator>Elliot A Hershberg</dc:creator>
      <dc:creator>Nuno M C Martins</dc:creator>
      <dc:creator>Paul L Reginato</dc:creator>
      <dc:creator>Mohammed Hannan</dc:creator>
      <dc:creator>Brian J Beliveau</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Evan R Daugharthy</dc:creator>
      <dc:creator>Marc A Marti-Renom</dc:creator>
      <dc:creator>C-Ting Wu</dc:creator>
      <dc:date>2020-07-29</dc:date>
      <dc:source>Nature methods</dc:source>
      <dc:title>3D mapping and accelerated super-resolution imaging of the human genome using in situ sequencing</dc:title>
      <dc:identifier>pmid:32719531</dc:identifier>
      <dc:identifier>pmc:PMC7537785</dc:identifier>
      <dc:identifier>doi:10.1038/s41592-020-0890-0</dc:identifier>
    </item>
    <item>
      <title>Publisher Correction: Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/32665711/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=None&amp;utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&amp;fc=None&amp;ff=20220523181312&amp;v=2.17.6</link>
      <description>An amendment to this paper has been published and can be accessed via a link at the top of the paper.</description>
      <content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Neurosci. 2020 Sep;23(9):1176. doi: 10.1038/s41593-020-0681-z.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">An amendment to this paper has been published and can be accessed via a link at the top of the paper.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/32665711/?utm_source=Other&utm_medium=rss&utm_content=0pm2ouqq_VKuV8ufStSbKkf-PnUydCRCFbkA13ov4u3&ff=20220523181312&v=2.17.6">32665711</a> | DOI:<a href=https://doi.org/10.1038/s41593-020-0681-z>10.1038/s41593-020-0681-z</a></p></div>]]></content:encoded>
      <guid isPermaLink="false">pubmed:32665711</guid>
      <pubDate>Thu, 16 Jul 2020 06:00:00 -0400</pubDate>
      <dc:creator>Elaine T Lim</dc:creator>
      <dc:creator>Mohammed Uddin</dc:creator>
      <dc:creator>Silvia De Rubeis</dc:creator>
      <dc:creator>Yingleong Chan</dc:creator>
      <dc:creator>Anne S Kamumbu</dc:creator>
      <dc:creator>Xiaochang Zhang</dc:creator>
      <dc:creator>Alissa M D'Gama</dc:creator>
      <dc:creator>Sonia N Kim</dc:creator>
      <dc:creator>Robert Sean Hill</dc:creator>
      <dc:creator>Arthur P Goldberg</dc:creator>
      <dc:creator>Christopher Poultney</dc:creator>
      <dc:creator>Nancy J Minshew</dc:creator>
      <dc:creator>Itaru Kushima</dc:creator>
      <dc:creator>Branko Aleksic</dc:creator>
      <dc:creator>Norio Ozaki</dc:creator>
      <dc:creator>Mara Parellada</dc:creator>
      <dc:creator>Celso Arango</dc:creator>
      <dc:creator>Maria J Penzol</dc:creator>
      <dc:creator>Angel Carracedo</dc:creator>
      <dc:creator>Alexander Kolevzon</dc:creator>
      <dc:creator>Christina M Hultman</dc:creator>
      <dc:creator>Lauren A Weiss</dc:creator>
      <dc:creator>Menachem Fromer</dc:creator>
      <dc:creator>Andreas G Chiocchetti</dc:creator>
      <dc:creator>Christine M Freitag</dc:creator>
      <dc:creator>Autism Sequencing Consortium</dc:creator>
      <dc:creator>George M Church</dc:creator>
      <dc:creator>Stephen W Scherer</dc:creator>
      <dc:creator>Joseph D Buxbaum</dc:creator>
      <dc:creator>Christopher A Walsh</dc:creator>
      <dc:date>2020-07-16</dc:date>
      <dc:source>Nature neuroscience</dc:source>
      <dc:title>Publisher Correction: Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder</dc:title>
      <dc:identifier>pmid:32665711</dc:identifier>
      <dc:identifier>doi:10.1038/s41593-020-0681-z</dc:identifier>
    </item>
  </channel>
</rss>
